Tobacco use is causally associated with cancers of the lung, larynx,mouth, esophagus, kidneys, urinary tract, and possibly, breast. Major classes of carcinogens present in tobacco and tobacco smoke are converted into DNA-reactive metabolites by cytochrome P450(CYP)-related enzymes, several of which display genetic polymorphism. Individual susceptibility to cancer is likely to be modified by the genotype for enzymes involved in the activation or detoxification of carcinogens in tobacco and repair of DNA damage. We summarize here the results of case-control studies published since 1990 on the effects of genetic variants of CYP1A1, 1A2, 1B1, 2A6, 2D6, 2E1, 2C9, 2C19, 17, and 19 alone or in combination with detoxifying enzymes as modifiers of the risk for tobacco-related cancers. The results of studies on gene-gene interactions and the dependence of smoking-related DNA adducts on genotype were also analyzed. Some CYP variants were associated with increased risks for cancers of the lung, esophagus, and head and neck. The risk was often increased in individuals who also had GSTM1 deficiency. For breast cancer in women, a few studies suggested an association with CYPs related to metabolism of tobacco carcinogens and steroidal hormones.

The overall effects of common CYP polymorphisms were found to be moderate in terms of penetrance and relative risk, with odds ratios ranging from 2 to 10. Some CYP1A1/GSTM1 0/0 genotype combinations seem to predispose the lung, esophagus, and oral cavity of smokers to an even higher risk for cancer or DNA damage,requiring, however, confirmation. Future strategies in molecular cancer epidemiology for identifying such susceptible individuals are discussed with emphasis on well-designed larger studies.

Epidemiological and human genetic studies have identified different types of population “at risk,” one consisting of individuals with heavy exposure to carcinogens, such as smokers and exposed workers, and the other consisting of carriers of cancer-predetermining germ-line mutations in genes that because of high penetrance confer a very high risk for cancer per se(1). There is also another group of predisposing polymorphic, low-penetrance genes, i.e., those involved in carcinogen metabolism and DNA repair, which modestly increase the risk for cancer in exposed individuals, perhaps at low doses of carcinogens (2, 3). In the latter case, the proportion of cancers attributable to such genetic traits may be high, because the frequency of “at risk” alleles in the population is high.

Drug-metabolizing enzymes, which often display genetic polymorphism, convert many tobacco carcinogens into DNA-binding metabolites in target cells and can thereby modulate intermediate effect markers such as DNA adducts and ultimately, the risk for cancer. The development of simple assays based on the PCR has allowed identification of individual genotypes for a variety of metabolic polymorphisms and studies on the modulation of cancer risk by environmental exposures, such as tobacco smoke, which are the subject of this review. Given the great number of carcinogen-activating and-detoxifying enzymes, the variation in their expression, and the complexity of exposures to tobacco carcinogens, assessment of a single polymorphic enzyme or genotype may not be sufficient to assess their role in carcinogenesis (reviewed in Ref. 4). Tobacco smoking is the major cause of lung cancer and is associated with risks for cancers of the larynx, mouth, esophagus, urinary bladder, and kidney (5). Breast cancer in women is at best weakly associated with cigarette smoking. We have included this site because recent studies suggested that postmenopausal women who are carriers of the CYP1A1 or NAT2 variant alleles may be at increased risk for breast cancer in a smoking-dose-related manner (6, 7).

Because major classes of tobacco carcinogens are converted to DNA-reactive metabolites by the oxidative, mainly CYP4-related enzymes, we have summarized studies of the effect of genetic polymorphism of CYPs in humans, alone or in combination with phase II enzymes, as risk modifiers of some major tobacco-related cancers. Our analysis includes case-control studies published from 1990 to May 1999 on cancers of the upper aerodigestive tract, urinary tract,and breast. To be included, a study had to have been published in a full article in English, cited in MedLine, and have involved a case-control design and adequate methods for analysis of CYPgenotype. When several overlapping reports on one study population were available, we included the most recent publication, which usually covered a larger number of study subjects. To obtain insights into mechanisms, we also briefly reviewed studies of gene-gene interactions and the dependence of the formation of smoking-related PAH-DNA adducts on genotype. Because of space limitations, the references cited are not exhaustive, and the reader is referred to review articles marked in the text.

These subjects have been reviewed by Hoffmann and Hecht (8, 9), McClellan (10), and Bergen and Caporaso (11). Processed tobacco contains over 3000 compounds including 30 carcinogens. The mainstream and sidestream smoke generated when tobacco in cigarettes is burnt contains more than 4000 constituents including about 50 carcinogens. The diversity of carcinogenic and toxic compounds in tobacco smoke leads to ambiguity about which are the most important; however, studies on the mechanisms of tobacco carcinogenesis and dosimetry in smokers and tobacco chewers indicate that three major classes of carcinogens, PAHs, TSNAs, and aromatic amines, play important roles in tobacco-associated cancers.

PAHs

The mechanism by which PAHs such as B[a]P interact with DNA, activate oncogenes, and initiate the carcinogenic process involves the formation of bay-region diolepoxides as the major ultimate carcinogens. B[a]P is converted into phenolic metabolites and B[a]P-7,8-diol by a CYP-mediated process. Secondary metabolism, mainly involving epoxide hydrolase and other CYP isoforms,leads to the formation of the highly reactive (+)-anti-BPDE. Several carcinogens present in tobacco smoke are inactivated by GSTs. The most frequently studied carcinogenic PAH diolepoxide, BPDE, is a relatively good substrate for GSTM1, M2, and M3 and better still for GSTP1(12).

Sensitive detection methods have been used to demonstrate the presence of smoking-related bulky (PAH)-DNA adducts in virtually all target organs of tobacco carcinogenesis. The amounts of(+)-anti-BPDE bound to DNA can be quantified by high-performance liquid chromatography with fluorescence detection by measuring the release of B[a]P-tetrols both from lung tissue and lymphocyte DNA (13). Subsequently, the complex interrelationship between PAH-DNA adduct levels, daily or total smoking dose, genotype, and cancer risk was studied (reviewed in Ref. 14).

TSNAs

This topic has been reviewed by McClellan (10) and Hecht (9, 15). NNK and NNN are the most important TSNAs. They originate mostly from unburned tobacco and are also pyrosynthesized during smoking. The exposure of smokers to TSNAs is much higher than that to other environmental nitrosamines. The evidence that TSNAs are causative in tobacco-induced cancers of the upper aerodigestive tract in humans is highly suggestive: NNK is a powerful lung carcinogen in all species tested; human exposure is comparable with the dose that causes tumors in laboratory animals; and the metabolic activation pathways of NNK are similar in humans and laboratory animals. NNK and NNN require metabolic activation to bind to DNA and express their carcinogenic effects. The metabolism of NNK includes α-methylhydroxylation, α-methylenehydroxylation,pyridine-N-oxidation by CYP-mediated reactions, and reduction to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its conjugation as glucuronide (reviewed in Refs. 9, 10, 11, 12, 13, 14, 15). The last compound can be detected in human urine and is a good indicator of exposure to NNK. N- and O-methylated DNA bases have been detected in many exposed tissues. In addition,pyridyl-oxobutylation of DNA and globin occurs after exposure to NNK or NNN. The keto alcohol released from globin or DNA after hydrolysis allows sensitive human dosimetry of these TSNAs in tobacco users. NNK-derived DNA adducts in humans have been characterized only partially (15).

Aromatic Amines

4-Aminobiphenyl and other aromatic amines are the components of smoke that appear to be primarily responsible for urinary bladder cancer in smokers. The key reactions by which the compounds are metabolized and produce DNA adducts in the bladder epithelium involve N-hydroxylation (CYP1A2) and N-acetylation (NAT1 and NAT2). The resulting hydroxylamine also reacts with hemoglobin to form 4-aminobiphenyl-hemoglobin adducts in smokers or may be further activated by O-acetylation to N-acetoxyarylamines, reactions that are also catalyzed by NAT1 and NAT2. Molecular dosimetry in smokers of black (air-cured) and blond (flue-cured) tobacco provided further evidence that aromatic amines induce bladder cancer in smokers. Smokers of black tobacco, who have a risk for bladder cancer that is two to three times that of smokers of blond tobacco, have 2-fold higher 4-aminobiphenyl-hemoglobin adduct levels and excrete twice as much mutagens in their urine(reviewed in Ref. 16). The 4-aminobiphenyl-DNA guanine adduct was detected as a major smoking-related adduct in biopsy samples from bladder cancer patients and in exfoliated urothelial cells of volunteers. The levels of adducts of 4-aminobiphenyl with hemoglobin and with DNA in the bladder were correlated, and both were related to recent cigarette smoking. The metabolic phenotypes of rapid or slow N-acetylator and rapid or slow N-oxidizer, CYP1A2, significantly affected the levels of 4-aminobiphenyl-hemoglobin and 4-aminobiphenyl-DNA adducts in the urothelium of smokers. Studies in aromatic amine-exposed workers and in smokers have shown previously that the slow acetylator phenotype (slow NAT2) is at higher risk for developing bladder cancer than those with the fast phenotype (reviewed in Ref. 17).

Oxidative and Lipid Peroxidation-induced DNA Damage

Like preformed carcinogens, tobacco smoke contains ROS and reactive nitrogen species that impose oxidative stress on smokers’tissue. As a consequence, oxidative DNA-base damage has been detected in respiratory tract tissue of smokers, with lipid peroxidation products such as malondialdehyde, crotonaldehyde, and trans-4-hydroxy-2-nonenal, the last of which can be further epoxidized by CYP-mediated reactions. These reactive aldehydes have been shown to form promutagenic exocyclic DNA adducts in human tissues (18, 19) and thus could contribute to carcinogenesis in the upper aerodigestive tract (20). Chewing of tobacco alone or with betel quid is causally associated with oral cancer;because chewing of betel quid generates large amounts of ROS in the mouth, TSNAs and ROS are the major genotoxic agents implicated in oral cancer related to chewing (reviewed in Ref. 21).

Because tobacco carcinogens, ROS, and lipid peroxidation products are likely to be substrates for GSTT1 or M1, the extent of DNA damage and ultimately the cancer risk may be affected by polymorphic CYPs and GST detoxifying enzymes (reviewed in Refs. 17 and 22).

Environmental Tobacco Smoke and Exposure to Low Doses of Carcinogens

Epidemiological studies have incriminated environmental tobacco smoke as a risk factor for lung cancer in nonsmokers. The concentrations of carcinogenic agents in such smoke appear to be low overall in comparison with those in undiluted mainstream smoke. Involuntary inhalation of tobacco smoke can occur over several hours/day. When comparing the ratio of concentration in sidestream and in mainstream smoke, relatively large amounts of carcinogenic, volatile nitrosamines and aromatic amines are released into sidestream smoke, as reflected by the concentrations of cotinine, a crude marker for uptake of tobacco carcinogens, in body fluids of passive smokers, which are about two orders of magnitude lower than those in active cigarette smokers (8). However, some data suggest that people with certain “at risk” genotypes are particularly susceptible to low doses of carcinogens (Ref. 2; reviewed in Ref. 3). This important health issue should be resolved by properly designed studies that would show whether passive smokers who have developed lung cancer are particularly susceptible.

Molecular Basis for Enzyme Polymorphisms

Some of the principal ways in which genetic polymorphism can affect the expression of gene products or the catalytic activity of the respective enzyme can be summarized as follows:

(a) Nucleotide variations in the coding region of the gene result in amino acid substitution and alter enzyme activity or substrate binding (e.g.,CYP2D6).

(b) Deletions in (of) the coding region lead to an inactive enzyme or lack of protein synthesis (e.g.,CYP2A6, CYP2D6, and GSTM1).

(c) Polymorphisms in the noncoding region affect transcriptional control elements involved in basal enzyme expression and induction (e.g.,CYP1A1).

(d) Variations in the polyadenylation signal of a gene affect transcript half-life and thus the quantity of enzyme(e.g.,NAT1).

(e) Gene amplification increases the quantity of enzyme(e.g.,CYP2D6).

(f) Complex interactions of polymorphic genes and/or their enzyme catalysis products (e.g.,GSTM1-deficient subjects or cells have greater induction of CYP1A1 and 1A2, probably because of greater bioavailability of inducer compounds).

Allelic CYP Variants and Effect on Cancer Risk in Tobacco Users

The role of particular human CYP450 in the metabolism of carcinogens has been reviewed (23, 24, 25). In the following,we evaluate case-control studies on the effect of polymorphic CYPs on the tobacco smoke-associated risk of cancers of the lung, larynx,mouth, esophagus, kidneys, urinary tract, and female breast. The past and recent systematic nomenclature for CYP1A1 polymorphisms is given in Table 1. For the purpose of clarity, we have referred to CYP1A1mutations by the system of Cascorbi et al.(26).5

CYP1A1.

The human enzyme CYP1A1, which is well conserved, is involved in the activation of major classes of tobacco procarcinogens, like PAHs and aromatic amines, and is present in many epithelial tissues. About 10%of the Caucasian population has a highly inducible form of the CYP1A1 enzyme (termed B[a]P-hydroxylase or previously arylhydrocarbon hydroxylase), which is associated with an increased risk for bronchial,laryngeal, and oral cavity tumors in smokers (reviewed in Ref. 27).

The induction of CYP1A1 is initiated by the specific binding of aromatic inducer compounds to the Ah receptor. An Ah receptor nuclear translocator (Arnt) gene is further involved in the CYP1A1 induction pathway. Thus far, no relationship has been found between Ah receptor polymorphism and lung cancer risk (28, 29).

Beginning in 1973 with the pioneering work by Kellerman et al.(30) on B[a]P hydroxylase inducibility and bronchogenic carcinoma, studies on the association of the genetic polymorphism of CYP1A1 and cancer started after cosegregation of the CYP1A1 high inducibility phenotype and polymorphism of the MspI restriction site (31).

The CYP1A1 Ile-Val (m2) mutation in the heme-binding region results in a 2-fold increase in microsomal enzyme activity and is in complete linkage disequilibrium in Caucasians with the CYP1A1 MspI (m1) mutation, which has also been associated experimentally with increased catalytic activity (32). Although the Ile-Val mutation in the CYP1A1 allele did not increase activity in vitro(33, 34), it might be linked to other functional polymorphisms, for example in the regulatory region important for CYP1A1 inducibility. Smokers with the exon 7 Ile-Val mutation were found to have more PAH-DNA adducts in their WBCs than smokers without the variant (35). The amount of these adducts is also elevated in cord blood and placenta of newborns with the CYP1A1-MspI polymorphism (36). In lung parenchymal tissue of smokers, the concentrations of BPDE and bulky(PAH)-DNA adducts were positively correlated with CYP1A1 enzyme activity (13). Significant ethnic differences in the frequency of homozygous CYP1A1 MspI alleles have been observed, and both the MspI and Val alleles are rarer in Caucasian than in Japanese populations (26).

A proposal has been made for a mechanism whereby the CYP1A1genotype and GSTM1 0/0 gene-gene interactions result in a greater-than-additive risk for DNA damage and cancer; in human cells,deletion of GSTM1 is associated with strong inducibility of CYP1A1 gene transcription by 2,4,7,8-tetrachlorodibenzo-para-dioxin (37). When BPDE-DNA adduct levels were measured in lung tissue of smokers, a significant interaction between deficiency of the GSTM1phenotype and high CYP1A1 inducibility or CYP1A1allelic variants was observed (38, 39), leading to very high adduct levels in Caucasians with CYP1A1/MspI/MspI-GSTM1 0/0 [see“ CYP1A1-GSTM1 Genotype Dependence of Bulky (PAH)-DNA Adduct Levels and of Other Effect Markers in Smokers”]. These data suggest that this “at risk” genotype combination predisposes to an increased risk for tobacco-associated DNA damage and lung cancer.

Lung Cancer.

The relationship between CYP1A1 variants and lung cancer risk in various ethnic populations has been examined in more than 20 studies. Early Japanese studies pointed to an increased risk for lung cancer in association with both the m1 (Table 2, Table 2A study nos. 1 and 10) and m2 mutations (Table 2, study 4); the CYP1A1 genotype was particularly important at a low level of smoking and in the development of squamous cell carcinoma (Table 2,study 3). These findings were not confirmed in studies conducted in Norway (Table 2, study 2), Finland (Table 2, study 5), the United States (Table 2, study 6), and Sweden (Table 2, study 8), perhaps because of the much lower prevalence of the m1 allele in Caucasians. Larger studies in mixed American populations (Table 2,study nos. 16, 17, 18, and 20) do point to an increased risk for lung cancer among carriers of m1 alleles, whereas in Caucasian smokers in France, no significant association was observed for either m1 or m2 (Table 2, study 19). In two Brazilian populations, the presence of the m2 allele was significantly associated with an increased risk for lung cancer (Table 2, study 12). The African-American-specific m3 (*3) mutation was not associated with an increased risk for lung cancer overall in three studies (Table 2, study nos. 9, 13, and 21); however, in one of them, a significantly increased risk for adenocarcinoma was seen for carriers of the m3 mutation (Table 2, study 21), and the OR for lung cancer was 8.4 for the genotype m1/m1,m2 (*2A/*2B). In Chinese, the m1 and m2 mutations were not correlated with either allele or lung cancer risk (Table 2, study 24),whereas results from the Republic of Korea surprisingly showed a significantly decreased risk for lung cancer among carriers of the m2 allele (Table 2, study 25). A recently described m4 mutation in close proximity to m1 has thus far been investigated in only one study of Caucasians, in which it did not correlate with an increased risk for lung cancer (Table 2, study 14). It is possible that individuals carrying the m4 mutation were misclassified as carriers of the m2 mutation in earlier studies, in which allele-specific primers were used. The combined CYP1A1 variants (either m2 or m1) and GSTM1 0/0 genotype have been associated with a significantly increased risk for lung cancer (Table 2, study nos. 4, 7, and 11),especially squamous cell carcinoma (Table 2, study nos. 4 and 20) in Japanese populations.

Head and Neck Cancer.

The CYP1A1 enzyme is present in oral tissue (40), and CYP1A1 variants and cancer risk at these sites have been investigated in 11 studies. There was overrepresentation of the CYP1A1 Ile-Val variant among Caucasian patients with oral cancer, but the prevalence of the Ile-Val variant was significantly higher in nonsmokers than smokers, although the number of nonsmokers was low (Table 3, Table 3Astudy 2). Similarly, an increased prevalence of CYP1A1Val-Val variant was found among Japanese patients with head and neck cancers and especially those with pharyngeal cancer (Table 3, study 5). Individuals with the homozygous CYP1A1 MspI(m1/m1) variant were at significantly increased risk for oral squamous cell carcinoma, in particular after exposure to low concentrations of PAH. The combination of homozygous CYP1A1 MspI (m1/m1) variant and GSTM1 0/0 further increased the risk. The buccal mucosa and upper gingiva appear to be the most susceptible tissues in carriers of the risk genotype (Table 3,study 6). The highest prevalence of p53 mutation was observed in oral tumors from patients with the CYP1A1(Val)/GSTM1 active genotype (41).

Esophageal Cancer.

Studies in Caucasians and Japanese showed no association with esophageal cancer. Esophageal cancer patients in China who were heavy smokers had a 3-fold higher frequency of the CYP1A1 Val-Val variant. The risk was further increased in patients with the combination of CYP1A1 Val-Val and GSTM1 0/0 genotypes (Table 4, study 4).

Urinary Tract Cancer.

Two studies of Japanese and Caucasians showed no significant associations (Table 5, study nos. 1 and 2). High CYP1A1 expression, as determined by immunohistochemistry, correlated with the grade of urinary bladder tumor (42).

Breast Cancer.

None of four studies of the effect of the m2 allele in Caucasian populations found a significant association overall (Table 6, Table 6Astudy nos. 1–4), but a significant increase in risk was found among postmenopausal women who were light smokers and carried the m2 allele (Table 6, study 2). These results were not confirmed in a smaller study of Caucasians, but an increased risk for breast cancer was found among African-American women with the homozygous m1/m1 genotype (Table 6, study 3). Bailey et al. (Ref. 43; Table 6, study 4),investigating m1, m2, m3, and m4 in Caucasian and African-American women, found no significant association, nor did the largest study, nested within the Nurses’ Health Study (Table 6, study 5), although in the latter study an increased risk was found for smoking at a young age and the presence of m1 and/or m2. A recent study of the m2 allele in postmenopausal women (Table 6, study 2) showed a significant correlation between above-median serum concentrations of polychlorinated biphenyls, the m2 allele, and breast cancer risk (Table 6, study 6).

Taken together, there is increasing evidence that the homozygous CYP1A1 (MspI and Ile-Val) genotypes are at higher risk for contracting smoking-associated lung (squamous cell carcinoma),head and neck, and esophageal cancers, as particularly seen in Asian study populations where these “at risk” allele frequencies are 8–18 times higher than in Caucasians. The cancer risk was further increased in the combined “at risk” CYP1A1-GSTM1 0/0 genotypes. The underlying mechanism of this genetic predisposition in these “at risk” smokers is supported by a higher prevalence of p53 mutations and B[a]P-DNA adducts (see “CYP1A1-GSTM1 Genotype Dependence of Bulky (PAH)-DNA Adduct Levels and of Other Effect Markers in Smokers”). For breast cancer risk, the available studies conducted on CYP1A1 variants mostly in Caucasians did not reveal an overall association.

CYP1A2.

This isoform activates many dietary and tobacco procarcinogens, notably aromatic and heterocyclic amines, and also metabolizes nicotine. Human CYP1A2 has 72% sequence identity with CYP1A1and, in contrast to extrahepatic CYP1A1, CYP1A2 appears to be expressed mainly in the liver and only weakly in the peripheral lung (44). Like CYP1A1, CYP1A2 is regulated in part by the Ah-receptor system and is induced in humans by a variety of chemicals. The activity of this enzyme can be determined in a noninvasive assay involving measurement of caffeine 3-demethylation.

Recently, a genetic polymorphism in the 5′ flanking region of the human CYP1A2 was identified that affects inducibility (45). Another single nucleotide polymorphism was found in intron 1, which is associated with high catalytic activity when subjects are exposed to tobacco smoke (46, 47). Individuals who are homozygous for the high inducibility genotype were shown to account for ∼45% of healthy Caucasians. A subgroup of smokers had a 1.6-fold increase in the caffeine demethylation ratio(ratio of paraxanthine:caffeine in serum) over that in nonsmokers.

Gene-gene interactions between GSTM1 0/0 and CYP1A2 and CYP1A1 enzyme induction have been observed in smokers; GSTM1 deficiency not only led to increased hepatic CYP1A2 activity in current smokers but also to significantly increased levels of bulky PAH-DNA adducts in lung parenchyma of smokers and ex-smokers, over that in individuals with wild-type GSTM1(4, 38, 39, 48). CYP1A2 activity was higher in GSTM1 0/0 subjects after exposure to cigarette smoke and heterocyclic amines from cooked meat. Exposed individuals with CYP1A1Ile-Val alleles had greater CYP1A2 activity than those with wild-type CYP1A1(49). GSTM1 0/0 led to higher levels of 4-aminobiphenyl-hemoglobin adducts in smokers (50). Such gene-gene interactions are probably attributable to a greater bioavailability of aromatic inducer compounds in GSTM1 0/0 subjects, leading to a higher rate of induction of CYP1A1 and CYP1A2 in smokers, which in turn increases macromolecular carcinogen binding.

Urinary Tract Cancer.

In one preliminary case-control study (Table 5, study 3), patients with the intron 1 variant had an OR of 1.7 for bladder cancer if they were smokers; if they also had the slow NAT2 phenotype, the OR was 2.2.

CYP1B1

CYP1B1, 1A2, and 3A4 all catalyze 2- and 4-hydroxylation of 17β-estradiol, but 4-hydroxylation is selectively catalyzed by CYP1B1. This enzyme activates many PAH-dihydrodiols, aromatic amines,and other groups of procarcinogens. CYP1B1 is also induced by Ah-receptor ligands. This enzyme is expressed in human kidney,prostate, ovary, and breast, and three CYP1B1 polymorphisms have been identified in exon 3, two of which are associated with amino acid substitutions, i.e., Val432Leu and Asn453Ser in the heme-binding domain of the enzyme (51).

Breast Cancer.

In the only study conducted thus far, no association was found with the CYP1B1 genotype. Caucasian patients with the codon 432 Val-Val genotype were more likely to have breast tumors containing estrogen and progesterone receptors (Table 6, study 7).

CYP2A6.

In humans, CYP2A6 mediates 7-hydroxylation of coumarin, a component of cigarette smoke, and activates several nitrosamines in tobacco smoke,including NNK (15, 52). The catalytic selectivity of CYP2A6 appears to overlap with that of CYP2E1. The location of CYP2A6 and 2E1 in extrahepatic tissues such as lung, nasal and pharyngeal areas is of interest. Two CYP2A6 variant alleles have been identified (*2 and *3). The prevalence of the Leu160His variant allele in Caucasians is ∼2%,and it is associated with lower coumarin 7-hydroxylation activity. A new allele has been described in which exons 5–9 are deleted (53). Individuals lacking functional CYP2A6have impaired nicotine metabolism and may thus be protected against tobacco dependence. In one study using a disputed genotyping method,carriers of the variant allele were reported to smoke fewer cigarettes (54). These findings were not confirmed in another study (55). The discrepancy could be resolved by newly available genotyping methods (56, 57).

Lung Cancer.

The only case-control study published thus far (Table 7, Table 7Astudy 1) showed no associations with CYP2A6*2.

CYP2D6.

Individuals with the PM phenotype (i.e., deficient in debrisoquine 4-hydroxylation) were first reported in 1984 to have a lowered risk for lung cancer (58). The PM phenotype,inherited as an autosomal recessive trait, is attributable to several defective allelic CYP2D6 variants, three of which account for >90% of all PM individuals. The mutations that cause loss of gene function are attributable mainly to two point mutations that result in CYP2D6*3 (formerly A) and CYP2D6*4(B) alleles and deletion of the entire CYP2D6*5 allele (D). A CYP2D6*2xn (L2) allele associated with 2–12-fold amplification of the CYP2D6 gene is found in carriers known as UMs (59). Conflicting data exist on whether CYP2D6 is expressed in human lung (60). Most searches for procarcinogens that are activated by CYP2D6 have been unsuccessful. It can activate the tobacco-specific nitrosamine NNK and also nicotine, but other P-450s are more active in this respect.

Associations have been found between nicotine depen-dence and PM (61) and between UM and smoking addiction (62). These findings may make establishing causality between this polymorphism and cancer risk more complex.

Lung Cancer.

Nine genotyping studies have been conducted, including several with large samples and with control for confounding factors. In three studies (Table 7, study nos. 3, 4, and 6), a significant association was found between lung cancer and EM genotype, and in one study an association with UM genotype and lung cancer risk was found for African-Americans (Table 7, study 8). Legrand Andreoletti et al. (Ref. 63; Table 7, study 9) screened over 40 alleles in cases and controls. They found no significant association for lung cancer overall, but the *1A/*2-EM genotype combination was significantly associated with lung cancer. Two meta-analysis showed no association or one of borderline significance between the EM genotype and increased risk (64, 65).

Head and Neck Cancer.

One of three studies of Caucasians showed a significantly higher frequency of the PM genotype among cases (Table 3, study 9).

Urinary Tract Cancer.

One of four studies showed an association only with the HEM (Table 7,study 4). The HEM genotype in smokers was associated with more aggressive bladder tumors (66).

Breast Cancer.

One American study (Table 6, study 8) of alleles *3, *4 and *5 showed no association with the CYP2D6 genotype, whereas a slightly larger study in Spain (Table 6, study 9) of alleles *3, *4 and *9 showed a significant association with HEM.

Analyses of all results on CYP2D6 genotype and lung cancer risk found no or a borderline protective effect of the PM genotype. For other cancer sites, the association with disease susceptibility was inconclusive.

CYP2E1.

The ethanol-inducible CYP2E1 metabolizes many known procarcinogens, including NNN, NNK, and other volatile nitrosamines found in tobacco smoke. Chlorzoxazone 6-hydroxylation is catalyzed by CYP2E1. Wide interindividual variation in the expression of the CYP2E1 gene has been reported in humans, which is possibly attributable to gene-environment interaction. CYP2E1 is induced in mice exposed to cigarette smoke by inhalation (67). Its regulation involves complex transcriptional and posttranscriptional mechanisms. Although in Caucasians no relationship was found between in vivo activity of this enzyme and genotype, in Japanese the presence of the variant c2 alleles resulted in a significant reduction in the oral clearance of chlorzoxazone, after adjustment for age and sex. The mean activity in individuals with the c2/c2 genotype was significantly lower than that in individuals with either the homozygous wild-type or the heterozygote genotype. Body weight and dietary factors were the major modulators of interindividual variation (68).

The human CYP2E1 gene is functionally well conserved, but several polymorphic alleles occurring at low frequency have now been identified. The RFLPs, revealed by either RsaI G–1259C or PstI C–1091T, are located in the 5′ flanking transcription region of this gene and appear to be in complete linkage disequilibrium with each other (c1, common allele; c2, rare allele). Although the primary sequence of the enzyme is not altered, increased gene transcription has been suggested (69). A T-7668A substitution in intron 6 of the CYP2E1 gene is revealed by a DraI RFLP (C, minor allele; D, common allele). The RsaI and the DraI polymorphisms appear to be linked, i.e., individuals with the RsaI polymorphism also had a mutant DraI allele, although the reverse is not true. A TaqI RFLP at position 9930 (intron 7)of the CYP2E1 gene has been reported, but no phenotype has been associated with this mutation.

Lung Cancer.

The wild-type DraI genotype was associated with an increased risk for lung cancer in 3–5 of 16 studies in Japanese,Mexican-Americans, and mixed populations (Table 7, study nos. 11, 13,16, 24, and 25). More conflicting results have been published concerning the RsaI/PstI mutation. The rare PstI/RsaI c2 allele has been associated with decreased risk for cancer in two studies of 11 (Table 7, study nos. 23 and 25), and in one study the c2 allele frequency was significantly lower among cases than controls (Table 7,study 15); however, in an additional study, the c2/c2genotype correlated positively with p53 mutations and with squamous cell carcinoma (Table 7, study 21). Additionally, in one small study the c2/c2 genotype was associated with adenocarcinoma(Table 7, study 22).

Head and Neck Cancer.

Five studies showed no association between head and neck cancer and CYP2E1 variants; however, Chinese patients who were not betel quid chewers had a higher prevalence of the c2 allele(PstI/RsaI; Table 3, study 11).

Esophageal Cancer.

The c2 allele was overrepresented among Chinese esophageal cancer patients (Table 4, study 9).

Urinary Tract Cancer.

Three studies found no association with bladder cancer. One study in Caucasian women revealed a higher risk for renal carcinomas among those with DraI variants (OR, 8.0; Table 5, study 10).

Breast Cancer.

The only study of the DraI polymorphism in Caucasians (Table 6, study 10) found a significant association among premenopausal smokers only (OR, 11.1).

Because the frequencies of variant alleles are very low in Caucasians and African-Americans, the statistical power of the studies is low. Altogether, conflicting results have been reported on the importance of CYP2E1 genotypes in well-documented tobacco-related cancers.

CYP2C9.

The levels of all smoking-related DNA adducts in the larynx were correlated with the presence of P4502C protein, suggesting a role of CYP2C9 in DNA adduction of PAH-type tobacco carcinogens (70). Two mutant alleles, CYP2C9*2(Arg144Cys) and *3(Ile359Leu), have been described, and CYP2C9 has a specific substrate, tolbutamide. The level of bulky DNA adducts in normal bronchial tissue of smokers was found to be higher in individuals with the homozygous CYP2C9*3/*3 genotype (71).

Lung Cancer.

One of two large (Table 7, study 27), well-designed studies in African-Americans and Caucasians (Table 7, study nos. 27 and 28)revealed an association of the *2 allele with borderline-increased risk(OR, 1.6).

CYP2C19.

Members of the human CYP2C gene subfamily are constitutively expressed, and at least seven human CYP2C genes may exist. Several defective CYP2C19 alleles are the basis for the(S)-mephenytoin 4′-hydroxylase polymorphism. In addition to(S)-mephenytoin, CYP2C19 also metabolizes a variety of clinically used drugs. The most common variant allele, *2, has an aberrant splice site in exon 5 (72). The premature stop codon mutant *3 allele has thus far been found only in Asians (73).

Lung and Bladder Cancer.

A very small study on Japanese patients (Table 7, study 29) revealed a significant association of the PM genotype with squamous cell carcinoma of the lung, but the association with bladder cancer seen in Caucasians was not found (Table 5, study 11).

CYP3A4.

This isoform is the major P450 expressed in human liver and small intestine. It can activate numerous procarcinogenic PAH dihydrodiols,such as BPDE, and also metabolizes NNN (74). Whether genetic or solely environmental factors are responsible for the wide variation in human 3A4 activity is unknown. Although the three CYP3A genes, 3A4, 3A5, and 3A7, are expressed at widely different levels, polymorphism has been found only for CYP3A4 and CYP3A5 to date. Several allelic variants of the CYP3A4 gene were reported (75), but none was apparently related to catalytic activity in the liver samples from which the DNA was derived. No extensive studies on CYP3A4 polymorphism have been reported.

CYP17.

This gene codes for the cytochrome P450C17α-enzyme, which mediates both steroid 17α-hydroxylase and 17,20-lyase activities and functions at key branch points in human steroidogenesis. The 5′-U terminal repeat of CYP17 contains a 1-bp polymorphism that creates a recognition site for the MspAI restriction enzyme and has been used to designate two alleles, A1 and A2. Premenopausal women with CYP17A2 variants have higher serum concentrations of estradiol and progesterone (76).

Breast Cancer.

Four studies in mainly Caucasian populations (Table 6, study nos. 12–15) and one in a mixed Hawaiian population (Table 6, study 11)showed no association with the CYP17 genotype.

CYP19.

This gene encodes aromatase, which is responsible for the rate-limiting step in the metabolism of C19 steroids to estrogens. Aromatase activity has been found in a number of tissues, including normal and transformed breast tissue. A common, high-heterozygosity tetranucleotide simple tandem repeat polymorphism in intron 4 has been described (77), but it is not known whether this polymorphism is associated with a specific phenotype.

Breast Cancer.

Two studies of the tandem repeat polymorphism in Caucasian women showed that an increased proportion of breast cancer patients had the short alleles; however, the allele frequencies varied greatly between the two study populations (Table 6, study nos. 16 and 17).

The genotype dependence of various effect markers, such as DNA adducts, cytogenetic damage and p53 mutations, have been studied, most effort having been focused on PAH-(BPDE)-DNA adducts related to tobacco smoking. Overall, the data indicate that smokers have higher PAH-DNA adduct levels in target tissues and leukocytes than ex- and nonsmokers (Table 8). The increased formation and the wide variation in levels of PAH-DNA adducts in some smokers occupationally exposed to PAH suggest that polymorphisms in genes related to PAH metabolism lead to increased DNA binding and cancer risk (reviewed in Ref. 14).

The relationship between CYP1A1 variants, alone or in combination with GSTM1, and the formation of bulky (PAH)-DNA adducts in human tissues (autopsy tissues excluded) and leukocytes remained controversial for some time (Table 8). Several studies showed a weak or no effect of m1 and m2 on adduct levels(Table 8, study nos. 3, 4, 6, 8 and 9). More recent studies, in which specific, sensitive detection methods were used (such as for(+)-anti-BPDE-DNA adducts), have shown clearly the dependence of adduct levels on CYP1A1 genotype, which is most pronounced in GSTM1-deficient smokers. Lung and leukocytes of Caucasian smokers with the CYP1A1m1/m1-GSTM1 0/0 combination clearly contained more BPDE-DNA adducts (Table 8, study nos. 1, 2, and 5). One study in which an ELISA was used (Table 8, study 7) showed a similar effect of m2-GSTM1 combinations.

In bronchial tissues of smokers with highly induced CYP1A1 enzyme and GSTM1 0/0, the BPDE-DNA levels were 100-fold higher than in subjects with active GSTM1 (Table 8, study 2). Another study found no effect of the CYP1A1 [MspI(m1) or Ile-Val (m2) mutations] or GSTM1 0/0 genotypes on bulky DNA adduct levels, when the 32P-postlabeling method was used (Table 8, study 3); however, carriers of homozygous CYP1A1m1 had higher BPDE-DNA adduct levels than individuals with the wild type(Table 8, study 1).

Studies of leukocytes from mostly Caucasians exposed to PAH, including smokers and nonsmokers, gave contradictory results (Table 8). No effect of m1 and m2 was observed in leukocyte DNA from lung cancer patients (Table 8, study 11), but a significant, 2-fold increase in PAH-DNA adduct level was found when m2 variants were combined with GSTM1 0/0 or wild type (Table 8, study 7). Heterozygous m1 or m2 variants were associated with an increase in the median BPDE adduct level when compared with the wild type (180). One Caucasian subject with the very rare m1/m1 genotype in combination with GSTM1 0/0 had an extremely high level of BPDE adducts:44/108 nucleotides (Table 8, study 5).

Overall, the data are compatible with the assumption that GSTM1 0/0 is a moderately strong susceptibility factor but may become a dominant risk factor in the presence of certain gene-gene combinations. This results in increased DNA damage and mutational events in target and surrogate tissues (leukocytes). These findings provide a mechanistic background why such “at risk” genotypes correlate with increased risks for tobacco-related lung cancer, even at a low level of cigarette smoking (Ref. 78, Table 2). This was seen more clearly in Japanese populations where the “at risk” alleles occur much more frequently than in Caucasians.

A suggested gender difference in lung cancer susceptibility was supported by a study showing that female smokers had a significantly higher level of aromatic DNA adducts in lung tissue than males at an equal cigarette smoking dose (pack-year; Ref. 79).

Lung tumors in Japanese smokers were found to harbor significantly more p53 mutations in people who had the susceptible CYP1A1 genotype. Individuals with the combination of CYP1A1m2/m2 and GSTM1 0/0 genotypes had an 8-fold greater frequency of p53 mutations than persons with neither genotype (80). Also, lung cancer patients with this “at risk” genotype combination who had undergone an operation had a remarkably shortened survival (81). Shorter survival of operated lung cancer patients with high pulmonary CYP1A1 enzyme inducibility was reported previously (82).

Taken together, because an elevated DNA and mutational damage associated with the “at risk” alleles has been found in both Asian and Caucasian smokers, large-scale studies should prove the prediction that carriers of (homozygous) CYP1A1variants/GSTM1 0/0 combinations of any ethnicity could be at an increased risk for tobacco-related (lung, head, and neck) cancers.

Molecular epidemiology has contributed to a growing awareness of the importance of relatively common genetic and acquired susceptibility factors in modulating risks associated with exposure to environmental carcinogens. Because cancer is largely a preventable disease, the future challenge of molecular epidemiology is to analyze individuals who are exposed to carcinogens for a combination of genotypes associated with susceptibility to cancer. It is evident that use of more precisely measurable intermediary risk markers, like DNA adducts,cytogenetic damage, and mutations, rather than cancer as an end point,will allow the identification of combinations of cancer-relevant genes that positively or negatively affect cancer outcome in humans. Such associations could then be verified in epidemiological studies designed to address the association or hypothesis to be confirmed. Thus, further progress is expected from studies in which biomarkers for carcinogen exposure, early biological effects, and susceptibility are integrated,which should allow establishment of the risk profiles of individuals and subgroups in given exposure situations.

Many of the published studies listed in Tables 2,3,4,5,6,7,8 have shortcomings that should be avoided in future, if possible. Furthermore, there is a bias against publishing (and citing) the absence of correlations. IARC (83, 84) provided state-of-the-art reviews of the application of biomarkers and the design and analysis of molecular epidemiological studies. The prerequisites for proper study design and conduct include: (a) clear definition of representative study populations and controls; (b) a sample size adequate to provide enough statistical power; (c) proper documentation (or measurement) of exposure; (d) avoidance of confounding because of use of study subjects of mixed ethnic background; and (e) study only of gene polymorphisms that have been shown to lead to altered phenotypic expression.

Rapid advances in high-throughput gene analysis by DNA chip technology will speed up the identification of new mutations in predisposing cancer genes. The main task, however, will be to characterize the functional significance of these gene variants in humans. Such efforts are under way, e.g., the Environmental Genome Project pursued by the National Institute for Environmental Health Sciences in the United States (85). The aims are to define genetic variation in a selected number of (∼200) genes in the American population and to relate them to disease risk and individual susceptibility, particularly in combination with specific chemical and physical exposures.

Knowledge of the prevalence and distribution of common genetic susceptibility factors and the ability to identify susceptible individuals or subgroups will have substantial preventive implications,in particular if more data are collected to show that people with certain “at risk” genotypes are more susceptible to low levels of exposure (see “Environmental Tobacco Smoke and Exposure to Low Doses of Carcinogens”). It is conceivable that such subjects could be:(a) more easily persuaded to avoid hazardous exposure like tobacco use; (b) targeted for intensive smoking cessation programs; (c) be enrolled in chemoprevention trials; and(c) be involved in cancer screening programs that are not appropriate for the general population. However, before results of individual screening for genetic traits can be used efficiently to implement preventive measures, more cancer-predisposing genes need to be studied and gene-environment and gene-gene interactions elucidated. To this purpose, the need of well-designed, large-scale studies is emphasized.

1

Supported by the following sources, fellowships,or grants: Deutsches Krebsforschungszentrum (DKFZ)/International Agency for Research on Cancer (to U. N.), Deutsche Forschungsgemeinschaft and Verein zur Förderung der Krebsforschung (to A. R.), DKFZ (to M. R.), and the European Commission and Gottlieb Daimler-Carl Benz Stiftung (to H. W.).

                        
4

The abbreviations used are: CYP,cytochrome P-450; PAH, polycyclic aromatic hydrocarbon; TSNA,tobacco-specific nitrosamine; B[a]P,benzo[a]pyrene; BPDE, benzo[a]pyrene diolepoxide; GST, glutathione S-transferase; NNK,4-methylnitrosamino-1,3-pyridyl-1-butanone; NNN, N′-nitrosonornicotine; NAT, N-acetyltransferase; ROS, reactive oxygen species; Ah,aromatic hydrocarbon; OR, odds ratio; PM, poor metabolizer; UM,ultraploid metabolizer; EM, extensive metabolizer; HEM, heterozygous EM; RFLP, restriction fragment length polymorphism.

        
5

A complete description of CYPalleles is given at http://www.imm.ki.se./CYPalleles/.

Table 1

Overview of CYP1A1 nomenclature

Historical nomenclature of polymorphismPoint mutationsSystematic nomenclature for mutations from Cascorbi et al. (26), 1996Systematic nomenclature for alleles from Cascorbi et al. (26), 1996Nomenclature proposed by IARC (84), 1999Nomenclature proposed by Nebert et al. (86), 1999
Wild-type allele, m1 None wta *1 *1 *1 
MspI Allele 3′ non-coding region, m2 6235 T → C m1 *2A *2 *2A 
Ile → Val, exon 7, codon 462 4889 A → G m2 *2B (m1+ m2b*3 (m2*2B (m1+ m2)*2C (m2
African-American specific allele, intron 7 5639 T → C m3 *3 *4 *3 
Thr → Asn, exon 7, codon 461 4887 C → A m4 *4 *5 *4 
Historical nomenclature of polymorphismPoint mutationsSystematic nomenclature for mutations from Cascorbi et al. (26), 1996Systematic nomenclature for alleles from Cascorbi et al. (26), 1996Nomenclature proposed by IARC (84), 1999Nomenclature proposed by Nebert et al. (86), 1999
Wild-type allele, m1 None wta *1 *1 *1 
MspI Allele 3′ non-coding region, m2 6235 T → C m1 *2A *2 *2A 
Ile → Val, exon 7, codon 462 4889 A → G m2 *2B (m1+ m2b*3 (m2*2B (m1+ m2)*2C (m2
African-American specific allele, intron 7 5639 T → C m3 *3 *4 *3 
Thr → Asn, exon 7, codon 461 4887 C → A m4 *4 *5 *4 
a

wt, wild type.

b

Mutation m2 is in strict linkage disequilibrium with mutation m1 in Caucasians.

Table 2

CYP1A1 and lung cancer

Study no.GeneMutations/alleleMajor cancer subtypesa(n)Country/ethnicitybCases/controls (n)Genotype frequenciesc (% in cases/controls)Significanced OR (95% CI)CommentsReferences
CYP1A1 m1 SCC (23) AC (21) SCLC (18) LCLC (6) Japanese 68/104 m1/m1: 23.5/10.6 wt/wt: 35.3/49.0 S m1/m1 vs. wt/wt + LC: 3.1 (CI not given)+ SCC: 4.6 (CI not given)  Kawajiri et al. (87), 1990 
CYP1A1 m1 SCC (80) SCLC (55) AC (46) LCLC (27) Norwegian 221/212 m1/m1: <1/<1 wt/wt: 77.8/78.8 NS m1/m1 and m1/wt vs. wt/wt and LC: 1.05 (0.67–1.67) Histological type, smoking habits and family history investigated; no association with m1 Tefre et al. (88), 1991 
CYP1A1 m1 SCC (57) AC (60) SCLC (24) LCLC (10) Japanese 151/375 m1/m1: 21.2/10.6 wt/wt: 40.4/44.3 NS but SCC, low doseof smoking and m1/m1 S: 7.31 (2.13–25.12) Patients with susceptible genotypes contracted carcinoma after fewer cigarettes, but no difference at high smoking dose Nakachi et al. (89), 1991 
CYP1A1 m2 SCC (67) AC (96) Japanese 212/358 m2/m2: 12.3/4.7 wt/wt: 56.6/65.1 S m2/m2: LC: 2.97 (1.59–5.57) SCC: 3.34 (1.49–7.52) AC: 2.54 (1.48–4.34) m2/m2+ GSTM1 0/0: LC: OR, 5.83 (CI, 2.28–13.3) SCC: OR, 9.07 (CI, 3.38–24.4) Hayashi et al. (90), 1992 
CYP1A1 m2 SCC (57) AC (37) SCLC (8) Finnish 106/122 m2/m2: 0/1.6 wt/wt: 78.3/78.7 NS  Hirvonen et al. (91), 1992; study population overlapping with Hirvonen et al. (92), 1992 and Hirvonen et al. (93), 1993 
CYP1A1 m1 SCC (29) AC (18) LCLC (4) SCLC (5) A-A (28/23) and Caucasian- Americans (28/25) 56/48 m1/m1: 3.5/6.2 wt/wt: 76.8/68.8 NS m1/m1 and m1/wt vs. ;7q>wt/wt LC: 0.7 (0.3–1.6)  Shields et al. (94), 1993 
CYP1A1 m1, m2 SCC only Japanese 85/170 m1:m1/m1: 22.4/8.8 wt/wt: 38.8/48.2 m2:m2/m2: 10.6/3.5 wt/wt: 58.8/64.7 S m1/m1: lower smoking dose: 6.55 (2.49–17.24); higher smoking dose 8.32 (2.34–29.62) m2/m2: lower smoking dose 8.46 (2.48–28.85); higher smoking dose 8.46 (1.68–42.73) GSTM1 null+ CYP1A1 m1/m1: OR, 16 (CI, 3.76–68.02) GSTM1 null + CYP1A1 m2/m2: OR, 41 (CI, 8.68–193.61) each at low smoking dose Nakachi et al. (95), 1993 
CYP1A1 m1, m2 SCC (107) AC (84) SCLC (58) Swedish 296/329 healthy controls+ 79 hospital controls m1:m1/m1: 1.3/0.3 wt/wt: 83.8/83.9 m2:m2/m2: 0/0 wt/wt: 94.6/93.0 NS OR for SCC before age 66, for m1/wt among GSTM1 0/0 OR, 3.0 (CI, 1.2–7.2) Alexandrie et al. (96), 1994 
CYP1A1 m3 Newly diagnosed, previously untreated LC, no histological restrictions A-A in USA 72/97 m3/m3: 1.4/2.1 wt/wt: 83.3/76.3 NS m3/m3 and m3/wt vs. wt/wt 0.64 (0.3–1.4)  Kelsey et al. (97), 1994 
10 CYP1A1 m1 SCC (86) AC (147) SCLC (8) LCLC (21) Japanese 267/151 m1/m1: 16.9/10.6 wt/wt: 36.7/44.3 S m1/m1 and m1/wt: 1.71 (1.07–2.69) Same control group as Nakachi et al. (89), 1991 Okada et al. (98), 1994 
11 CYP1A1 m1, m2 SCC (71) SCLC (47) Japanese 118/331 (185 smoking controls) m1:m1/m1: 16.5/17.8ewt/wt: 37.1/43.8em2:m2/m2: 5.3/6.0ewt/wt: 61.1/55.5e NS For m2/m2 and GSTM1 0/0 OR, 21.9 (CI, 4.68–112.7) Kihara et al. (78), 1995 
Study no.GeneMutations/alleleMajor cancer subtypesa(n)Country/ethnicitybCases/controls (n)Genotype frequenciesc (% in cases/controls)Significanced OR (95% CI)CommentsReferences
CYP1A1 m1 SCC (23) AC (21) SCLC (18) LCLC (6) Japanese 68/104 m1/m1: 23.5/10.6 wt/wt: 35.3/49.0 S m1/m1 vs. wt/wt + LC: 3.1 (CI not given)+ SCC: 4.6 (CI not given)  Kawajiri et al. (87), 1990 
CYP1A1 m1 SCC (80) SCLC (55) AC (46) LCLC (27) Norwegian 221/212 m1/m1: <1/<1 wt/wt: 77.8/78.8 NS m1/m1 and m1/wt vs. wt/wt and LC: 1.05 (0.67–1.67) Histological type, smoking habits and family history investigated; no association with m1 Tefre et al. (88), 1991 
CYP1A1 m1 SCC (57) AC (60) SCLC (24) LCLC (10) Japanese 151/375 m1/m1: 21.2/10.6 wt/wt: 40.4/44.3 NS but SCC, low doseof smoking and m1/m1 S: 7.31 (2.13–25.12) Patients with susceptible genotypes contracted carcinoma after fewer cigarettes, but no difference at high smoking dose Nakachi et al. (89), 1991 
CYP1A1 m2 SCC (67) AC (96) Japanese 212/358 m2/m2: 12.3/4.7 wt/wt: 56.6/65.1 S m2/m2: LC: 2.97 (1.59–5.57) SCC: 3.34 (1.49–7.52) AC: 2.54 (1.48–4.34) m2/m2+ GSTM1 0/0: LC: OR, 5.83 (CI, 2.28–13.3) SCC: OR, 9.07 (CI, 3.38–24.4) Hayashi et al. (90), 1992 
CYP1A1 m2 SCC (57) AC (37) SCLC (8) Finnish 106/122 m2/m2: 0/1.6 wt/wt: 78.3/78.7 NS  Hirvonen et al. (91), 1992; study population overlapping with Hirvonen et al. (92), 1992 and Hirvonen et al. (93), 1993 
CYP1A1 m1 SCC (29) AC (18) LCLC (4) SCLC (5) A-A (28/23) and Caucasian- Americans (28/25) 56/48 m1/m1: 3.5/6.2 wt/wt: 76.8/68.8 NS m1/m1 and m1/wt vs. ;7q>wt/wt LC: 0.7 (0.3–1.6)  Shields et al. (94), 1993 
CYP1A1 m1, m2 SCC only Japanese 85/170 m1:m1/m1: 22.4/8.8 wt/wt: 38.8/48.2 m2:m2/m2: 10.6/3.5 wt/wt: 58.8/64.7 S m1/m1: lower smoking dose: 6.55 (2.49–17.24); higher smoking dose 8.32 (2.34–29.62) m2/m2: lower smoking dose 8.46 (2.48–28.85); higher smoking dose 8.46 (1.68–42.73) GSTM1 null+ CYP1A1 m1/m1: OR, 16 (CI, 3.76–68.02) GSTM1 null + CYP1A1 m2/m2: OR, 41 (CI, 8.68–193.61) each at low smoking dose Nakachi et al. (95), 1993 
CYP1A1 m1, m2 SCC (107) AC (84) SCLC (58) Swedish 296/329 healthy controls+ 79 hospital controls m1:m1/m1: 1.3/0.3 wt/wt: 83.8/83.9 m2:m2/m2: 0/0 wt/wt: 94.6/93.0 NS OR for SCC before age 66, for m1/wt among GSTM1 0/0 OR, 3.0 (CI, 1.2–7.2) Alexandrie et al. (96), 1994 
CYP1A1 m3 Newly diagnosed, previously untreated LC, no histological restrictions A-A in USA 72/97 m3/m3: 1.4/2.1 wt/wt: 83.3/76.3 NS m3/m3 and m3/wt vs. wt/wt 0.64 (0.3–1.4)  Kelsey et al. (97), 1994 
10 CYP1A1 m1 SCC (86) AC (147) SCLC (8) LCLC (21) Japanese 267/151 m1/m1: 16.9/10.6 wt/wt: 36.7/44.3 S m1/m1 and m1/wt: 1.71 (1.07–2.69) Same control group as Nakachi et al. (89), 1991 Okada et al. (98), 1994 
11 CYP1A1 m1, m2 SCC (71) SCLC (47) Japanese 118/331 (185 smoking controls) m1:m1/m1: 16.5/17.8ewt/wt: 37.1/43.8em2:m2/m2: 5.3/6.0ewt/wt: 61.1/55.5e NS For m2/m2 and GSTM1 0/0 OR, 21.9 (CI, 4.68–112.7) Kihara et al. (78), 1995 
Table 2A

Continued

Study no.GeneMutations/alleleMajor cancer subtypesa (n)Country/ethnicitybCases/controls (n)Genotype frequenciesc (% in cases/controls)Significanced OR (95% CI)CommentsReferences
12 CYP1A1 m1, m2 Newly diagnosed and histologically confirmed LC Black, white, and mullato Brazilians 110/112 m1:m1/m1: 8/8 wt/wt: 63/63 m2:m2/m2: 2/2 m2/wt: 27/14 wt/wt: 71/84 S m2/m2+ m2/wt: 2.26 (1.14–4.47) m2/m2+ m2/wt in white Brazilians: 2.4 (1.15–4.98)  Sugimura et al. (99), 1995; Hamada et al. (100), 1995; study population overlapping with Sugimura et al. (101), 1994 
13 CYP1A1 m3 AC (51) SCC (35) SCLC (14) A-A 144/230 m3/m3 and m3/wt: 16.7/15.2 wt/wt: 83.3/84.8 NS m3/m3 and m3/wt vs. wt/wt LC: 1.3 (0.7–2.4) Strongest association with SCC, but NS London et al. (102), 1995 
14 CYP1A1 m1, m2, m3, m4 LC Caucasian 157/314 m3: 0/0 m4: 2.87/2.87 S m2: 3.01 (1.29–7.26) NS for m1, m3, m4  Cascorbi et al. (26), 1996 study population overlapping with Drakoulis et al. (103), 1994 
15 CYP1A1 m1 SCC (13) AC (15) SCLC (8) European 44/81 m1/m1: 2.3/2.5 wt/wt: 84.1/79.0 NS m1/m1 and m1/wt vs. wt/wt LC: 0.71 (0.27–1.87) CYP1A1 inducibility Significant association with risk for AC OR, 5.29 (CI, 1.27–22.00); for LC OR, 3.41 (CI, 1.19–9.75) Jacquet et al. (104), 1996 
16 CYP1A1 m1 AC (110) SSC (67) Mixed: Caucasian and “non-Caucasian” 207/283 m1/m1: 1.0/0.7 m1/wt: 16.9/17.0 wt/wt: 82.1/82.3 S for m1/wt+ m1/m1: for LC 2.08 (1.15–3.73)f; for light smokers with AC: 2.25 (1.13–4.48)f Positive association for each subtype of LC Xu et al. (105), 1996 
17 CYP1A1 m1 AC (225) SSC (116) SCLC (18) LCLC (23) Mostly white American 412/442 m1/m1: 1.0/1.0 m1/wt: 18.0/16.3 wt/wt: 81.0/82.7 S m1/wt and LC: 1.5 (1.0–2.3)f Includes data from Xu et al. (105), 1996 OR for m1/wt and GSTM1 null: OR, 1.9 (CI, 1.0–3.4) Garcia Closas et al. (106), 1997 
18 CYP1A1 m1, m2, m3 LC A-A and M-A 171/295 A-A: m1:m1/m1: 1.8/5.8 wt/wt: 60.6/63.5 m2:m2/wt: 3.7/3.7 wt/wt: 96.3/96.3 m3: m3/m3: 1.1/1.9 wt/wt: 81.5/77.9 M-A: m1:m1/m1: 16.1/17.1 wt/wt: 40.3/42.4 m2:m2/m2: 11.5/12.7 wt/wt: 44.3/46.2 NS A-A: OR for “presence of”: m1: 1.54 (0.78–3.03)fm2: 0.72 (0.11–4.79)fm3: 0.63 (0.24–1.62)f M-A: m1: 0.85 (0.4–1.78)fm2: 1.34 (0.63–2.84)f But m1/m1 and m1/wt in light smokers (≤30 PY) S: 2.03 (1.03–4.01)f  Ishibe et al. (107), 1997 
19 CYP1A1 m1, m2 SCC (98) SCLC (52) Caucasian (in France) 150/171 m1/m1: 0.7/0 m1/wt: 12.0/10.5 m1,m2/wt: 5.3/8.7 m1,m2/m1,m2: 1.3/0 wt/wt: 80.7/80.7 NS m1/m1 and m1/wt vs. wt/wt 0.9 (0.5–1.8)fm2/m2 and m2/wt vs. wt/wt 0.8 (0.3–1.9)f  Bouchardy et al. (108), 1997 
Study no.GeneMutations/alleleMajor cancer subtypesa (n)Country/ethnicitybCases/controls (n)Genotype frequenciesc (% in cases/controls)Significanced OR (95% CI)CommentsReferences
12 CYP1A1 m1, m2 Newly diagnosed and histologically confirmed LC Black, white, and mullato Brazilians 110/112 m1:m1/m1: 8/8 wt/wt: 63/63 m2:m2/m2: 2/2 m2/wt: 27/14 wt/wt: 71/84 S m2/m2+ m2/wt: 2.26 (1.14–4.47) m2/m2+ m2/wt in white Brazilians: 2.4 (1.15–4.98)  Sugimura et al. (99), 1995; Hamada et al. (100), 1995; study population overlapping with Sugimura et al. (101), 1994 
13 CYP1A1 m3 AC (51) SCC (35) SCLC (14) A-A 144/230 m3/m3 and m3/wt: 16.7/15.2 wt/wt: 83.3/84.8 NS m3/m3 and m3/wt vs. wt/wt LC: 1.3 (0.7–2.4) Strongest association with SCC, but NS London et al. (102), 1995 
14 CYP1A1 m1, m2, m3, m4 LC Caucasian 157/314 m3: 0/0 m4: 2.87/2.87 S m2: 3.01 (1.29–7.26) NS for m1, m3, m4  Cascorbi et al. (26), 1996 study population overlapping with Drakoulis et al. (103), 1994 
15 CYP1A1 m1 SCC (13) AC (15) SCLC (8) European 44/81 m1/m1: 2.3/2.5 wt/wt: 84.1/79.0 NS m1/m1 and m1/wt vs. wt/wt LC: 0.71 (0.27–1.87) CYP1A1 inducibility Significant association with risk for AC OR, 5.29 (CI, 1.27–22.00); for LC OR, 3.41 (CI, 1.19–9.75) Jacquet et al. (104), 1996 
16 CYP1A1 m1 AC (110) SSC (67) Mixed: Caucasian and “non-Caucasian” 207/283 m1/m1: 1.0/0.7 m1/wt: 16.9/17.0 wt/wt: 82.1/82.3 S for m1/wt+ m1/m1: for LC 2.08 (1.15–3.73)f; for light smokers with AC: 2.25 (1.13–4.48)f Positive association for each subtype of LC Xu et al. (105), 1996 
17 CYP1A1 m1 AC (225) SSC (116) SCLC (18) LCLC (23) Mostly white American 412/442 m1/m1: 1.0/1.0 m1/wt: 18.0/16.3 wt/wt: 81.0/82.7 S m1/wt and LC: 1.5 (1.0–2.3)f Includes data from Xu et al. (105), 1996 OR for m1/wt and GSTM1 null: OR, 1.9 (CI, 1.0–3.4) Garcia Closas et al. (106), 1997 
18 CYP1A1 m1, m2, m3 LC A-A and M-A 171/295 A-A: m1:m1/m1: 1.8/5.8 wt/wt: 60.6/63.5 m2:m2/wt: 3.7/3.7 wt/wt: 96.3/96.3 m3: m3/m3: 1.1/1.9 wt/wt: 81.5/77.9 M-A: m1:m1/m1: 16.1/17.1 wt/wt: 40.3/42.4 m2:m2/m2: 11.5/12.7 wt/wt: 44.3/46.2 NS A-A: OR for “presence of”: m1: 1.54 (0.78–3.03)fm2: 0.72 (0.11–4.79)fm3: 0.63 (0.24–1.62)f M-A: m1: 0.85 (0.4–1.78)fm2: 1.34 (0.63–2.84)f But m1/m1 and m1/wt in light smokers (≤30 PY) S: 2.03 (1.03–4.01)f  Ishibe et al. (107), 1997 
19 CYP1A1 m1, m2 SCC (98) SCLC (52) Caucasian (in France) 150/171 m1/m1: 0.7/0 m1/wt: 12.0/10.5 m1,m2/wt: 5.3/8.7 m1,m2/m1,m2: 1.3/0 wt/wt: 80.7/80.7 NS m1/m1 and m1/wt vs. wt/wt 0.9 (0.5–1.8)fm2/m2 and m2/wt vs. wt/wt 0.8 (0.3–1.9)f  Bouchardy et al. (108), 1997 
Table 2B

Continued

Study no.GeneMutations/alleleMajor cancer subtypesa (n)Country/ethnicitybCases/controls (n)Genotype frequenciesc (% in cases/controls)Significanced OR (95% CI)CommentsReferences
20 CYP1A1 m1, m2 SCC (74) AC (162) SCLC (51) Caucasian, Japanese, Hawaian 341/456 m1:m1/m1: 10.3/9.7 m1/wt: 35.7/35.2 wt/wt: 54.0/55.1 m2:m2/m2: 1.8/2.9 wt/wt: 78.0/74.0 NS m1/m1 vs. wt/wt 1.2 (0.6–2.2)fm1/wt vs. wt/wt 1.3 (0.9–1.9)fm2/m2 vs. wt/wt 0.7 (0.2–2.3)fm2/wt vs. wt/wt 1.0 (0.6–1.5)f but m1/m1 and m1/wt and SCC: S: 2.4 (1.2–4.7) m1/m1 and m1/wt+ GSTM1 null+ SCC: OR, 3.1 (CI, 1.2–7.9)f Le Marchand et al. (109), 1998 
21 CYP1A1 m1, m2, m3 SCC (37) AC (41) LCLC (8) SCLC (7) A-A 96/278 m1/m1: 6.2/6.0 m1/wt: 20.8/27.0 m1/m3: 5.2/3.6 m1/m2: 0/4.7 m1/m1,m2: 3.0/0.4 m1/m3,m3: 1.0/0 m1/m2,m3: 1.0/0 m2/m2: 1.0/0 m2/wt: 3.0/1.1 m3/m3: 0/0.4 m3/wt: 10.5/10.4 wt/wt: 47.9/46.4 NS m1/wt vs. wt/wt: 1.2 (0.7–2.2)fm1/m1 vs. wt/wt: 1.3 (0.5–3.5)f ORs for “presence of”: m2: 1.1 (0.4–2.7)fm3: 1.5 (0.7–3.2)f but m3/m3 and m3/wt+ AC: S: 2.8 (1.3–6.5)f m1/m1 and m2/wt: OR, 8.4 (CI, 1.6–43.2)f Taioli et al. (110), 1998; study population overlapping with Taioli et al. (111), 1995 
22 CYP1A1 m2 SCC (122) SCLC (28) AC (78) Japanese from Okinawa 247/185 m2/m2: 11.3/3.8 m2/wt: 38.1/45.4 wt/wt: 50.6/50.8 S m2/m2+ LC: 3.3 (1.3–8.6)f + SCC: 4.9 (1.4–16.3)f + SCLC: 9.4 (2.1–42.0)f  Sugimura et al. (112), 1998 
23 CYP1A1 m1, m2 SCC (30) AC (56) SCLC (16) LCLC (6) Japanese 108/95 m1:m1/m1: 22.2/10.5 wt/wt: 36.1/na m2: m2/m2: 16.7/6.3 wt/wt: 53.7/na S m1/m1 and LC: 2.93 (1.26–6.84)fm2/m2 and LC: 3.45 (1.29–9.25)f  Kiyohara et al. (113), 1998 
24 CYP1A1 m1, m2 AC (38) SCLC (18) SCC (14) Chinese 76/122 m1:m1/m1: 12/11 wt/wt: 43/44 m2:m2/m2: 8/4 wt/wt: 66/65 NS m1/wt vs. wt/wt: 0.84 (0.44–1.60) m1/m1 vs. wt/wt: 0.99 (0.37–2.61) m1,m2/wt vs. wt/wt: 0.83 (0.44–1.59) m1,m2/m1,m2 vs. wt/wt 1.81 (0.58–5.71) Combined analysis of CYP1A1 variants and GSTM1 “0”: NS Persson et al. (114), 1999 
25 CYP1A1 m1, m2 SCC (27) SCLC (15) AC (28) Korean 85/63 m1:m1/m1: 7/5 wt/wt: 40/46 m2:m2/m2: 1/2 m2/wt: 80/95 wt/wt: 19/3 S m2/m2 or m2/wt: 0.14 (0.03–0.64) Combined analysis of CYP1A1 m1 alleles and GSTM1 “0”: NS Very high frequency of m2/wt-m2 distribution not in Hardy-Weinberg equilibrium m1 and m2 mutations are not in complete linkage disequilibrium Hong et al. (115), 1998 
Study no.GeneMutations/alleleMajor cancer subtypesa (n)Country/ethnicitybCases/controls (n)Genotype frequenciesc (% in cases/controls)Significanced OR (95% CI)CommentsReferences
20 CYP1A1 m1, m2 SCC (74) AC (162) SCLC (51) Caucasian, Japanese, Hawaian 341/456 m1:m1/m1: 10.3/9.7 m1/wt: 35.7/35.2 wt/wt: 54.0/55.1 m2:m2/m2: 1.8/2.9 wt/wt: 78.0/74.0 NS m1/m1 vs. wt/wt 1.2 (0.6–2.2)fm1/wt vs. wt/wt 1.3 (0.9–1.9)fm2/m2 vs. wt/wt 0.7 (0.2–2.3)fm2/wt vs. wt/wt 1.0 (0.6–1.5)f but m1/m1 and m1/wt and SCC: S: 2.4 (1.2–4.7) m1/m1 and m1/wt+ GSTM1 null+ SCC: OR, 3.1 (CI, 1.2–7.9)f Le Marchand et al. (109), 1998 
21 CYP1A1 m1, m2, m3 SCC (37) AC (41) LCLC (8) SCLC (7) A-A 96/278 m1/m1: 6.2/6.0 m1/wt: 20.8/27.0 m1/m3: 5.2/3.6 m1/m2: 0/4.7 m1/m1,m2: 3.0/0.4 m1/m3,m3: 1.0/0 m1/m2,m3: 1.0/0 m2/m2: 1.0/0 m2/wt: 3.0/1.1 m3/m3: 0/0.4 m3/wt: 10.5/10.4 wt/wt: 47.9/46.4 NS m1/wt vs. wt/wt: 1.2 (0.7–2.2)fm1/m1 vs. wt/wt: 1.3 (0.5–3.5)f ORs for “presence of”: m2: 1.1 (0.4–2.7)fm3: 1.5 (0.7–3.2)f but m3/m3 and m3/wt+ AC: S: 2.8 (1.3–6.5)f m1/m1 and m2/wt: OR, 8.4 (CI, 1.6–43.2)f Taioli et al. (110), 1998; study population overlapping with Taioli et al. (111), 1995 
22 CYP1A1 m2 SCC (122) SCLC (28) AC (78) Japanese from Okinawa 247/185 m2/m2: 11.3/3.8 m2/wt: 38.1/45.4 wt/wt: 50.6/50.8 S m2/m2+ LC: 3.3 (1.3–8.6)f + SCC: 4.9 (1.4–16.3)f + SCLC: 9.4 (2.1–42.0)f  Sugimura et al. (112), 1998 
23 CYP1A1 m1, m2 SCC (30) AC (56) SCLC (16) LCLC (6) Japanese 108/95 m1:m1/m1: 22.2/10.5 wt/wt: 36.1/na m2: m2/m2: 16.7/6.3 wt/wt: 53.7/na S m1/m1 and LC: 2.93 (1.26–6.84)fm2/m2 and LC: 3.45 (1.29–9.25)f  Kiyohara et al. (113), 1998 
24 CYP1A1 m1, m2 AC (38) SCLC (18) SCC (14) Chinese 76/122 m1:m1/m1: 12/11 wt/wt: 43/44 m2:m2/m2: 8/4 wt/wt: 66/65 NS m1/wt vs. wt/wt: 0.84 (0.44–1.60) m1/m1 vs. wt/wt: 0.99 (0.37–2.61) m1,m2/wt vs. wt/wt: 0.83 (0.44–1.59) m1,m2/m1,m2 vs. wt/wt 1.81 (0.58–5.71) Combined analysis of CYP1A1 variants and GSTM1 “0”: NS Persson et al. (114), 1999 
25 CYP1A1 m1, m2 SCC (27) SCLC (15) AC (28) Korean 85/63 m1:m1/m1: 7/5 wt/wt: 40/46 m2:m2/m2: 1/2 m2/wt: 80/95 wt/wt: 19/3 S m2/m2 or m2/wt: 0.14 (0.03–0.64) Combined analysis of CYP1A1 m1 alleles and GSTM1 “0”: NS Very high frequency of m2/wt-m2 distribution not in Hardy-Weinberg equilibrium m1 and m2 mutations are not in complete linkage disequilibrium Hong et al. (115), 1998 
a

SCC, squamous cell carcinoma; AC,adenocarcinoma; SCLC, small cell lung cancer; LCLC, large cell lung cancer; LC, lung cancer.

b

A-A, African-American.

c

wt, wild type; M-A, Mexican-American.

d

S, significant; NS, not significant; CI,confidence interval; PY, pack years.

e

Values for smoking controls(n = 185).

f

Data adjusted for confounding factors such as smoking, age, gender, and others (for details, refer to original publication).

Table 3

CYPs and head and neck cancers

Study no.GeneMutation/alleleCancer sitea(n)Country/ethnicityCases/controls (n)Genotype frequencies (% cases/controls)Significanceb OR (95% CI)CommentsReferences
CYP1A1 m1 Upper aerodigestive tract cancer French Caucasians  96/202 Allele frequencies m1: 0.12/0.12 NS Alcoholic controls NS alcoholic controls (202) vs. normal controls (260) 0.12/0.087 Lucas et al. (145), 1996 
CYP1A1 m2 Oral cancer SCC (112) Larynx (23) United States Caucasians 131/131 wt/m2+ m2/m2 All: 17.6/7.6 M: 12.9/7.1 F: 26.1/8.7 S All: 2.6 (1.2–5.7) F: 3.7 (1.1–12.5) Higher prevalence of wt/m2 + m2/m2 in nonsmoker cases vs. smoker cases; OR, 0.3 (CI, 0.1–1.0) Park et al. (146), 1997 
CYP1A1 m1                  m2 Upper aerodigestive tract. Oral/pharynx (126) Larynx (272) (Total cases) German Caucasians 398/219 m1/m1: 0.3/1.0 wt/wt: 84/89.8 m2/m2: 0.5/1.0 wt/wt: 85/85.5 NS m1/m1+ m1wt/wtwt Oral/pharynx 0.6 (0.3–1.3)c Larynx 0.6 (0.3–1.1)cm2m2+ m2wt/wtwt Oral/pharynx 1.3 (0.6–2.6)c Larynx 0.8 (0.5–2.6)c No interaction between CYP1A1 and GSTM1 or CYP1A1 and smoking. Matthias et al. (147), 1998 
CYP1A1 m1                  m2 SCC (185) Larynx (73) Oral and oropharynx (76) Other subsites (36) Dutch Caucasians 185/207 Allele frequencies m1: 0.178/0.159 wt: 0.822/0.841 m2: 0.184/0.164 wt: 0.816/0.836 NS P = 0.71 NS: in combination with GSTM1 and GSTT1 Oude Ophuis et al. (148), 1998 
CYP1A1 m2 SCC Larynx (69) Hypo/oropharynx (45) Tongue (22) Oral cavity (12) Japanese 145/164 All: n = 145 m2/m2: 9/3.7 wt/m2: 25/33 wt/wt: 66/63 Pharynx: n = 45 m2/m2: 13/3.7 wt/m2: 31/33 wt/wt: 56/63 m2/m2 vs. m2/wt+ wt/wt S SCC 4.1 (1.1–15) P = 0.038 S Pharynx 5.7 (1.1–28) P = 0.034 NS Logistic regression analysis of cases with multiple vs. single tumors; with age, gender, smoking, ethanol, CYP1A1, CYP2E1, GSTM1, GSTP1 and NAT2 as covariates Morita et al. (149), 1999 
CYP1A1 m1 Oral SCC Lower gingiva (30) Tongue (29) Floor of the mouth (21) Buccal mucosa (11) Upper gingiva (9) Japanese 100/100 m1/m1: 15/8 wt/wt: 32/62 S: m1/m1 in cases vs. controls 3.6 (1.4–9.5) m1/m1 and GSTM1 0/0 S: 4.3 (1.0–17.4) S: in cases, smoking dose for m1/m1 was significantly less than smoking dose for wt/wt S: m1/m1 in combination with GSTM1 0/0; 4.3 (1.0–17.4) S: for various subsites of oral cancer except floor of the mouth ORs ranging from 2.3 (tongue) to 46.5 (buccal mucosa) Tanimoto et al. (150), 1999 
CYP2D6 *4 Pharynx (35) Larynx (35) Mouth-floor (5) Spanish Caucasians  75/200 PM: 4/3 EM: 82/76 NS Cases all male NS: Control 150 M vs. 50 F NS: Pharynx vs. larynx Gonzalez et al. (151), 1998 
CYP2D6 *3 *4 Upper aerodigestive tract. Oral/pharynx (126) Larynx (272) German Caucasians 398/219 PM: 6.2/5.8 EM: 59/58.1 NS Oral/pharynx PM: 0.7 (0.2–2.1)c EM: 1-1 (0.7–1.8)c Larynx PM: 1.1 (0.5–2.6)c EM: 1.1 (0.8–1.7)c  Matthias et al. (147), 1998 
CYP2D6 *3,*4,*5 Oral SCC British Caucasians 100/467 PM: 13/4.5 EM: 66/63 S: PM in cases vs. controls 3.2 (1.6–6.5) P = 0.001 S: in cases <65 yr PM greater and EM less than in cases >65 yr P = 0.009 Time to lymph node metastasis shorter in PM compared with EM Alcohol or smoking had no effect. Worrall et al. (152), 1998 
Study no.GeneMutation/alleleCancer sitea(n)Country/ethnicityCases/controls (n)Genotype frequencies (% cases/controls)Significanceb OR (95% CI)CommentsReferences
CYP1A1 m1 Upper aerodigestive tract cancer French Caucasians  96/202 Allele frequencies m1: 0.12/0.12 NS Alcoholic controls NS alcoholic controls (202) vs. normal controls (260) 0.12/0.087 Lucas et al. (145), 1996 
CYP1A1 m2 Oral cancer SCC (112) Larynx (23) United States Caucasians 131/131 wt/m2+ m2/m2 All: 17.6/7.6 M: 12.9/7.1 F: 26.1/8.7 S All: 2.6 (1.2–5.7) F: 3.7 (1.1–12.5) Higher prevalence of wt/m2 + m2/m2 in nonsmoker cases vs. smoker cases; OR, 0.3 (CI, 0.1–1.0) Park et al. (146), 1997 
CYP1A1 m1                  m2 Upper aerodigestive tract. Oral/pharynx (126) Larynx (272) (Total cases) German Caucasians 398/219 m1/m1: 0.3/1.0 wt/wt: 84/89.8 m2/m2: 0.5/1.0 wt/wt: 85/85.5 NS m1/m1+ m1wt/wtwt Oral/pharynx 0.6 (0.3–1.3)c Larynx 0.6 (0.3–1.1)cm2m2+ m2wt/wtwt Oral/pharynx 1.3 (0.6–2.6)c Larynx 0.8 (0.5–2.6)c No interaction between CYP1A1 and GSTM1 or CYP1A1 and smoking. Matthias et al. (147), 1998 
CYP1A1 m1                  m2 SCC (185) Larynx (73) Oral and oropharynx (76) Other subsites (36) Dutch Caucasians 185/207 Allele frequencies m1: 0.178/0.159 wt: 0.822/0.841 m2: 0.184/0.164 wt: 0.816/0.836 NS P = 0.71 NS: in combination with GSTM1 and GSTT1 Oude Ophuis et al. (148), 1998 
CYP1A1 m2 SCC Larynx (69) Hypo/oropharynx (45) Tongue (22) Oral cavity (12) Japanese 145/164 All: n = 145 m2/m2: 9/3.7 wt/m2: 25/33 wt/wt: 66/63 Pharynx: n = 45 m2/m2: 13/3.7 wt/m2: 31/33 wt/wt: 56/63 m2/m2 vs. m2/wt+ wt/wt S SCC 4.1 (1.1–15) P = 0.038 S Pharynx 5.7 (1.1–28) P = 0.034 NS Logistic regression analysis of cases with multiple vs. single tumors; with age, gender, smoking, ethanol, CYP1A1, CYP2E1, GSTM1, GSTP1 and NAT2 as covariates Morita et al. (149), 1999 
CYP1A1 m1 Oral SCC Lower gingiva (30) Tongue (29) Floor of the mouth (21) Buccal mucosa (11) Upper gingiva (9) Japanese 100/100 m1/m1: 15/8 wt/wt: 32/62 S: m1/m1 in cases vs. controls 3.6 (1.4–9.5) m1/m1 and GSTM1 0/0 S: 4.3 (1.0–17.4) S: in cases, smoking dose for m1/m1 was significantly less than smoking dose for wt/wt S: m1/m1 in combination with GSTM1 0/0; 4.3 (1.0–17.4) S: for various subsites of oral cancer except floor of the mouth ORs ranging from 2.3 (tongue) to 46.5 (buccal mucosa) Tanimoto et al. (150), 1999 
CYP2D6 *4 Pharynx (35) Larynx (35) Mouth-floor (5) Spanish Caucasians  75/200 PM: 4/3 EM: 82/76 NS Cases all male NS: Control 150 M vs. 50 F NS: Pharynx vs. larynx Gonzalez et al. (151), 1998 
CYP2D6 *3 *4 Upper aerodigestive tract. Oral/pharynx (126) Larynx (272) German Caucasians 398/219 PM: 6.2/5.8 EM: 59/58.1 NS Oral/pharynx PM: 0.7 (0.2–2.1)c EM: 1-1 (0.7–1.8)c Larynx PM: 1.1 (0.5–2.6)c EM: 1.1 (0.8–1.7)c  Matthias et al. (147), 1998 
CYP2D6 *3,*4,*5 Oral SCC British Caucasians 100/467 PM: 13/4.5 EM: 66/63 S: PM in cases vs. controls 3.2 (1.6–6.5) P = 0.001 S: in cases <65 yr PM greater and EM less than in cases >65 yr P = 0.009 Time to lymph node metastasis shorter in PM compared with EM Alcohol or smoking had no effect. Worrall et al. (152), 1998 
Table 3A

Continued

Study no.GeneMutation/alleleCancer sitea (n)Country/ethnicityCases/controls (n)Genotype frequencies (% cases/controls)Significanceb OR (95% CI)CommentsReferences
10 CYP2E1 RsaI DraUpper aerodigestive tract cancer French Caucasians  96/202 Allele frequency c2: 0.040/0.044 C: 0.141/0.114 NS Alcoholic controls S: alcoholic controls (202) vs. normal controls (260) C: 0.141/0.079; P < 0.01 NS: but lower frequency of C allele in <45 yr cases (protective effect!) Lucas et al. (145), 1996 
11 CYP2E1 RsaOral cancer Taiwan Chinese: 71% Fukienese; 7% Hakka; and 22% mainland  41/123 c2/c2: 5/3 c1/c2: 46/34 c1/c1: 49/62 NS c1/c2+ c2/c2/c1/c1 1.8 (0.9–3.9)c but among nonchewers only c1/c2 and c2/c2 vs. c1/c1 S: 4.7 (1.1–20.2)cn = 7/40 Cases all male. Age and ethnicity adjusted; alcohol and betel-quid chewing investigated NS: combination with GSTM1 and/or GSTT1 Hung et al. (153), 1997 
12 CYP2E1 PstPharynx (35) Larynx (35) Mouth floor (5) Spanish Caucasians  75/200 c2/c2: 2/0 c1/c1: 90/90 NS  Gonzalez et al. (151), 1998 
13 CYP2E1 PstI, RsaI DraUpper aerodigestive tract. Oral/pharynx (126) Larynx (272) German Caucasians 398/219 c2/c2: 0.3/0 c1c1: 93.7/94.3 CC: 0.3/1.7 DD: 85/84.3 NS c1/c2+ c2/c2/c1/c1 Oral/Pharynx 0.9 (0.3–2.7)c Larynx 0.8 (0.3–1.9)cCD+ DD/DD Oral/pharynx 1.2 (0.6–2.5)c Larynx 1.3 (0.7–2.6)c Alcohol had no effect. Matthias et al. (147), 1998 
14 CYP2E1 PstI, RsaSCC Larynx (69) Hypo/oropharynx (45) Tongue (22) Oral cavity (12) Japanese 145/164 c2/c2: 5.5/4.3 c1/c1: 62.8/64 NS All cases P = 0.4 Larynx P = 0.12 Pharynx P = 0.9 NS Logistic regression analysis of cases with multiple vs. single tumors; with age, gender, smoking, ethanol, CYP1A1, CYP2E1, GSTM1, GSTP1, and NAT2 as covariates. Morita et al. (149), 1999 
Study no.GeneMutation/alleleCancer sitea (n)Country/ethnicityCases/controls (n)Genotype frequencies (% cases/controls)Significanceb OR (95% CI)CommentsReferences
10 CYP2E1 RsaI DraUpper aerodigestive tract cancer French Caucasians  96/202 Allele frequency c2: 0.040/0.044 C: 0.141/0.114 NS Alcoholic controls S: alcoholic controls (202) vs. normal controls (260) C: 0.141/0.079; P < 0.01 NS: but lower frequency of C allele in <45 yr cases (protective effect!) Lucas et al. (145), 1996 
11 CYP2E1 RsaOral cancer Taiwan Chinese: 71% Fukienese; 7% Hakka; and 22% mainland  41/123 c2/c2: 5/3 c1/c2: 46/34 c1/c1: 49/62 NS c1/c2+ c2/c2/c1/c1 1.8 (0.9–3.9)c but among nonchewers only c1/c2 and c2/c2 vs. c1/c1 S: 4.7 (1.1–20.2)cn = 7/40 Cases all male. Age and ethnicity adjusted; alcohol and betel-quid chewing investigated NS: combination with GSTM1 and/or GSTT1 Hung et al. (153), 1997 
12 CYP2E1 PstPharynx (35) Larynx (35) Mouth floor (5) Spanish Caucasians  75/200 c2/c2: 2/0 c1/c1: 90/90 NS  Gonzalez et al. (151), 1998 
13 CYP2E1 PstI, RsaI DraUpper aerodigestive tract. Oral/pharynx (126) Larynx (272) German Caucasians 398/219 c2/c2: 0.3/0 c1c1: 93.7/94.3 CC: 0.3/1.7 DD: 85/84.3 NS c1/c2+ c2/c2/c1/c1 Oral/Pharynx 0.9 (0.3–2.7)c Larynx 0.8 (0.3–1.9)cCD+ DD/DD Oral/pharynx 1.2 (0.6–2.5)c Larynx 1.3 (0.7–2.6)c Alcohol had no effect. Matthias et al. (147), 1998 
14 CYP2E1 PstI, RsaSCC Larynx (69) Hypo/oropharynx (45) Tongue (22) Oral cavity (12) Japanese 145/164 c2/c2: 5.5/4.3 c1/c1: 62.8/64 NS All cases P = 0.4 Larynx P = 0.12 Pharynx P = 0.9 NS Logistic regression analysis of cases with multiple vs. single tumors; with age, gender, smoking, ethanol, CYP1A1, CYP2E1, GSTM1, GSTP1, and NAT2 as covariates. Morita et al. (149), 1999 
a

SCC, squamous cell carcinoma.

b

NS, not significant; S, significant.

c

Data adjusted for confounding factors such as smoking, age, gender, and others (for details, refer to original publication).

Table 4

CYPs and esophageal cancers

Study no.GeneMutation/alleleCancer siteCountry/ethnicityCases/controls (n)Genotype frequencies (% cases/controls)Significancea OR (95% CI)CommentsReferences
CYP1A1 m1 Esophageal cancer French Caucasians  62/202 Allele frequency m1: 0.12/0.14 NS Alcoholic controls NS: Alcoholic controls (202) vs. normal controls (260) 0.12/0.087 Lucas et al. (145), 1996 
CYP1A1 m1 m2 Esophageal cancer Japanese  94/70 m1:m1/m1: 11.7/21.4 wt/wt: 35.1/41.4 m2:m2/m2: 2.2/4.3 wt/wt: 57.1/60.0 NS  Hori et al. (154), 1997 
CYP1A1 m2 Esophagus SCCb Japanese  53/132 m2:m2/m2: 1.9/2.3 wt/wt: 60.4/60.6 NS m2/m2+ m2/wt vs. wt/wt 1.0 (0.5–1.9) NS: Genotype distribution in male smokers or alcohol drinkers NS: Multiple regression analysis of CYP2E1, CYP1A1, and GSTM1 with age alcohol and gender as covariates Morita et al. (155), 1997 
CYP1A1 m2 Esophageal carcinoma Chinese  89/137 m2:m2/m2: 15/5 wt/wt: 56/67 S m2/m2 cases vs. controls P < 0.05 S: m2/m2 and high smoking dose OR, 6.63 (CI, 1.86–23.7) P < 0.01 S: m2/m2 and GSTM1 0/0 and high smoking dose OR, 12.7 (CI, 1.97–81.8) P < 0.01 Nimura et al. (156), 1997 
CYP1A1 m1 m2 Esophageal carcinoma AC: 21 SCC: 13 Dutch Caucasians AC: 21/247 SCC: 13/247 AC: m1:m1/m1: 0/1 wt/wt: 67/84 m2:m2/m2: 0/1 wt/wt: 86/84 SCC: m1:m1/m1: 0/1 wt/wt: 61/84 m2:m2/m2: 0/1 wt/wt: 61/84 NS Very few cases Van Lieshout et al. (157), 1999 
CYP2E1 RsaI DraEsophageal cancer French Caucasians  62/202 Allele frequency c2: 0.040/0.00 C: 0.141/0.09 NS Alcoholic controls S: Alcoholic controls (202) vs. normal controls (260). C: 0.141/0.079 NS but lower frequency of C allele in <45 yr cases (protective effect ?) Lucas et al. (145), 1996 
CYP2E1 PstI, RsaEsophageal cancer Japanese  94/70 c2/c2: 7.6/1.4 c1/c1: 62/64.3 NS Also shown that S: ADH2/ADH2b OR, 6.2 (CI, 2.6–14.7) S: ALDH2b/ALDH2 OR, 4.4 (CI 2.5–7.7) S: Combination of two OR, 17.9 (P < 0.001) Hori et al. (154), 1997 
CYP2E1 PstI, RsaEsophagus SCC Japanese  53/132 c2/c2: 1.9/3.8 c1/c1: 64.2/64.4 NS c2c2+ c2c1 vs. c1c1 1.0 (0.5–2.0) NS: Genotype distribution in male smokers and alcohol drinkers NS: Multiple regression analysis of CYP2E1, CYP1A1, and GSTM1 with age alcohol and gender as covariates Morita et al. (155), 1997 
CYP2E1 RsaI DraEsophagus SCC or AC Chinese  45/46 c2/c2: 7/7 c1/c2: 13/49 c1/c1: 80/44 DD: 9/7 CC: 55/42 S c2/c2andc1/c2 vs. c1/c1 OR, 4.8 (CI,1.8–12.4) but NS for DraI CD+ DD/CC 1.5 (0.5–3.6)c Small study size S: 45 hyperplasia and dysplasia cases c2/c2and c1/c2 vs. c1/c1 OR, 6 (CI,2.3–16) S: 62 cancer+ advanced dysplasia c2/c2 and c1/c2 vs. c1/c1 OR, 4 (CI, 1.8–12.4) Lin et al. (158), 1998 
Study no.GeneMutation/alleleCancer siteCountry/ethnicityCases/controls (n)Genotype frequencies (% cases/controls)Significancea OR (95% CI)CommentsReferences
CYP1A1 m1 Esophageal cancer French Caucasians  62/202 Allele frequency m1: 0.12/0.14 NS Alcoholic controls NS: Alcoholic controls (202) vs. normal controls (260) 0.12/0.087 Lucas et al. (145), 1996 
CYP1A1 m1 m2 Esophageal cancer Japanese  94/70 m1:m1/m1: 11.7/21.4 wt/wt: 35.1/41.4 m2:m2/m2: 2.2/4.3 wt/wt: 57.1/60.0 NS  Hori et al. (154), 1997 
CYP1A1 m2 Esophagus SCCb Japanese  53/132 m2:m2/m2: 1.9/2.3 wt/wt: 60.4/60.6 NS m2/m2+ m2/wt vs. wt/wt 1.0 (0.5–1.9) NS: Genotype distribution in male smokers or alcohol drinkers NS: Multiple regression analysis of CYP2E1, CYP1A1, and GSTM1 with age alcohol and gender as covariates Morita et al. (155), 1997 
CYP1A1 m2 Esophageal carcinoma Chinese  89/137 m2:m2/m2: 15/5 wt/wt: 56/67 S m2/m2 cases vs. controls P < 0.05 S: m2/m2 and high smoking dose OR, 6.63 (CI, 1.86–23.7) P < 0.01 S: m2/m2 and GSTM1 0/0 and high smoking dose OR, 12.7 (CI, 1.97–81.8) P < 0.01 Nimura et al. (156), 1997 
CYP1A1 m1 m2 Esophageal carcinoma AC: 21 SCC: 13 Dutch Caucasians AC: 21/247 SCC: 13/247 AC: m1:m1/m1: 0/1 wt/wt: 67/84 m2:m2/m2: 0/1 wt/wt: 86/84 SCC: m1:m1/m1: 0/1 wt/wt: 61/84 m2:m2/m2: 0/1 wt/wt: 61/84 NS Very few cases Van Lieshout et al. (157), 1999 
CYP2E1 RsaI DraEsophageal cancer French Caucasians  62/202 Allele frequency c2: 0.040/0.00 C: 0.141/0.09 NS Alcoholic controls S: Alcoholic controls (202) vs. normal controls (260). C: 0.141/0.079 NS but lower frequency of C allele in <45 yr cases (protective effect ?) Lucas et al. (145), 1996 
CYP2E1 PstI, RsaEsophageal cancer Japanese  94/70 c2/c2: 7.6/1.4 c1/c1: 62/64.3 NS Also shown that S: ADH2/ADH2b OR, 6.2 (CI, 2.6–14.7) S: ALDH2b/ALDH2 OR, 4.4 (CI 2.5–7.7) S: Combination of two OR, 17.9 (P < 0.001) Hori et al. (154), 1997 
CYP2E1 PstI, RsaEsophagus SCC Japanese  53/132 c2/c2: 1.9/3.8 c1/c1: 64.2/64.4 NS c2c2+ c2c1 vs. c1c1 1.0 (0.5–2.0) NS: Genotype distribution in male smokers and alcohol drinkers NS: Multiple regression analysis of CYP2E1, CYP1A1, and GSTM1 with age alcohol and gender as covariates Morita et al. (155), 1997 
CYP2E1 RsaI DraEsophagus SCC or AC Chinese  45/46 c2/c2: 7/7 c1/c2: 13/49 c1/c1: 80/44 DD: 9/7 CC: 55/42 S c2/c2andc1/c2 vs. c1/c1 OR, 4.8 (CI,1.8–12.4) but NS for DraI CD+ DD/CC 1.5 (0.5–3.6)c Small study size S: 45 hyperplasia and dysplasia cases c2/c2and c1/c2 vs. c1/c1 OR, 6 (CI,2.3–16) S: 62 cancer+ advanced dysplasia c2/c2 and c1/c2 vs. c1/c1 OR, 4 (CI, 1.8–12.4) Lin et al. (158), 1998 
a

NS, not significant; S, significant.

b

SCC, squamous cell carcinoma; AC,adenocarcinoma; ADH2, alcohol dehydrogenase 2; ALDH2, aldehyde dehydrogenase 2.

c

Data adjusted for confounding factors such as smoking, age, gender, and others (for details, refer to original publication).

Table 5

CYPs and urinary tract cancer

Study no.GeneCancer siteMutation/alleleCountry/ethnicity (n)Cases/controls (n)Genotype/allele frequencies (% cases/controls)Significancea (OR and 95% CI)CommentsReferences
CYP1A1 Bladder, renal pelvis, and ureter m2 Japanese  83/101 m2/m2: 3.6/5.0 wt/wt: 60.3/56.4 NS  Katoh et al. (159), 1995 
CYP1A1 Bladder m1, m2 German Caucasians 374/373 m1/m1: 0.8/0.6 wt/wt: 83.7/83.9 m2/m2: 0.3/0 wt/wt: 95.6/94.4 NS m1wt+ m1m1: 0.9 (0.6–1.4)bm2wt + m2m2: 0.7 (0.3–1.4)b Effect on LC risk not modified by smoking or histological type Brockmöller et al. (160), 1996 
CYP1A2 Bladder Intron 1 German Caucasians 220/137 Data not given NS but for smokers borderline OR, 1.7 (CI not given) CYP1A2+ NAT slow; OR, 2.2 (CI not given) Brockmöller et al. (17), 1998 
CYP2D6 Bladder *4 British Caucasians 184/720 PM: 4.4/4.3 HEM: 41.8/29.6 EM: 53.8/66.1 S P = 0.005 only for HEM vs. EM  Smith et al. (116), 1992 
CYP2D6 Bladder *3,*4,*5 British Caucasians 126/132 PM: 10/6 HEM: 34/27 EM: 56/67 NS P = 212 Controls: non-bladder cancer outpatients Spurr et al. (161), 1995 
CYP2D6 Bladder *3,*4, *5 Egyptian  22/21 PM: 31.8/52.3 HEM: 22.7/19.0 EM: 45.5/28.6 NS EM: 2.4 (0.7–9.9) GSTM1 0/0 and CYP2D6 EM: OR, 14.0 (CI, 1.3–151) Anwar et al. (162), 1996 
CYP2D6 Bladder *3,*4,*5,*16, *2xn Caucasians in Germany 374/373 PM: 5.6/8.9 EM: 51.4/51.7 NSb Effect on LCc risk not modified by histological type or tumor grade or stage Brockmöller et al. (160), 1996 
CYP2E1 Bladder PstEgyptian 22/21 c2c2: 0/0 c1c1: 100/95.3 NS P = 0.48  Anwar et al. (162), 1996 
CYP2E1 Bladder PstI, RsaI, TaqGerman Caucasians 374/373 PstI: c2c2: 0/0 c1c1: 96.2/94.3 DraI: CC: 1.8/0.3 DD: 85.6/87.3 TaqI: A1A1: 0.8/0.3 A2A2: 77.6/74.1 NSa Effect on LC risk not modified by smoking or histological type Brockmöller et al. (160), 1996 
10 CYP2E1 Renal and urothelial DraI, PstGerman Caucasians 187 renal+ 38 urothelial cancer patients/304 Renal: DraI: CC: 1.1/0.7 DD: 84.0/86.2 PstI: c2c2: 0.5/0.0 c1c1: 93.0/95.1 Urothelial: DraI: CC: 0.0/0.7 DD: 86.8/86.2 PstI: c2c2: 0/0.0 c1c1: 97.4/95.1 Renal: NS c1c2: 1.3 (0.6–2.9)b but females S c1c2: 8.0 (1.6–39.2)b & C/D: 2.6 (1.3–5.3)b Urothelial: NSb  Farker et al. (163), 1998 
11 CYPC19 Bladder *2 German Caucasians 374/373 *2/*2: 1.7/3.5*1A/*1A: 67.9/71.5 NS*1A*1A +*1A*2: OR, 2.7 (CI, 0.9–7.7)b Effect on LC risk not modified by smoking or histological type Brockmöller et al. (160), 1996 
Study no.GeneCancer siteMutation/alleleCountry/ethnicity (n)Cases/controls (n)Genotype/allele frequencies (% cases/controls)Significancea (OR and 95% CI)CommentsReferences
CYP1A1 Bladder, renal pelvis, and ureter m2 Japanese  83/101 m2/m2: 3.6/5.0 wt/wt: 60.3/56.4 NS  Katoh et al. (159), 1995 
CYP1A1 Bladder m1, m2 German Caucasians 374/373 m1/m1: 0.8/0.6 wt/wt: 83.7/83.9 m2/m2: 0.3/0 wt/wt: 95.6/94.4 NS m1wt+ m1m1: 0.9 (0.6–1.4)bm2wt + m2m2: 0.7 (0.3–1.4)b Effect on LC risk not modified by smoking or histological type Brockmöller et al. (160), 1996 
CYP1A2 Bladder Intron 1 German Caucasians 220/137 Data not given NS but for smokers borderline OR, 1.7 (CI not given) CYP1A2+ NAT slow; OR, 2.2 (CI not given) Brockmöller et al. (17), 1998 
CYP2D6 Bladder *4 British Caucasians 184/720 PM: 4.4/4.3 HEM: 41.8/29.6 EM: 53.8/66.1 S P = 0.005 only for HEM vs. EM  Smith et al. (116), 1992 
CYP2D6 Bladder *3,*4,*5 British Caucasians 126/132 PM: 10/6 HEM: 34/27 EM: 56/67 NS P = 212 Controls: non-bladder cancer outpatients Spurr et al. (161), 1995 
CYP2D6 Bladder *3,*4, *5 Egyptian  22/21 PM: 31.8/52.3 HEM: 22.7/19.0 EM: 45.5/28.6 NS EM: 2.4 (0.7–9.9) GSTM1 0/0 and CYP2D6 EM: OR, 14.0 (CI, 1.3–151) Anwar et al. (162), 1996 
CYP2D6 Bladder *3,*4,*5,*16, *2xn Caucasians in Germany 374/373 PM: 5.6/8.9 EM: 51.4/51.7 NSb Effect on LCc risk not modified by histological type or tumor grade or stage Brockmöller et al. (160), 1996 
CYP2E1 Bladder PstEgyptian 22/21 c2c2: 0/0 c1c1: 100/95.3 NS P = 0.48  Anwar et al. (162), 1996 
CYP2E1 Bladder PstI, RsaI, TaqGerman Caucasians 374/373 PstI: c2c2: 0/0 c1c1: 96.2/94.3 DraI: CC: 1.8/0.3 DD: 85.6/87.3 TaqI: A1A1: 0.8/0.3 A2A2: 77.6/74.1 NSa Effect on LC risk not modified by smoking or histological type Brockmöller et al. (160), 1996 
10 CYP2E1 Renal and urothelial DraI, PstGerman Caucasians 187 renal+ 38 urothelial cancer patients/304 Renal: DraI: CC: 1.1/0.7 DD: 84.0/86.2 PstI: c2c2: 0.5/0.0 c1c1: 93.0/95.1 Urothelial: DraI: CC: 0.0/0.7 DD: 86.8/86.2 PstI: c2c2: 0/0.0 c1c1: 97.4/95.1 Renal: NS c1c2: 1.3 (0.6–2.9)b but females S c1c2: 8.0 (1.6–39.2)b & C/D: 2.6 (1.3–5.3)b Urothelial: NSb  Farker et al. (163), 1998 
11 CYPC19 Bladder *2 German Caucasians 374/373 *2/*2: 1.7/3.5*1A/*1A: 67.9/71.5 NS*1A*1A +*1A*2: OR, 2.7 (CI, 0.9–7.7)b Effect on LC risk not modified by smoking or histological type Brockmöller et al. (160), 1996 
a

NS, not significant; S, significant.

b

Data adjusted for confounding factors such as smoking, age, gender, and others (for details, refer to original publication).

c

LC, lung cancer.

Table 6

CYPs and breast cancer in women

Study no.GeneMutation/alleleCountry/ethnicityaCases/controlsb (n)Genotype frequency (% cases/controls)Significancec OR (95% CI)CommentsReferences
CYP1A1 m2 Caucasian  96/126 Allele frequency m2: 0.01/0 NS  Rebbeck et al. (164), 1994 
CYP1A1 m2 United States Caucasian 216/282 m2/m2: 2/1 wt/wt: 80/85 NS m2/m2 and m2/wt vs. wt/wt 1.61 (0.94–2.75)d but for light smokers (up to 29 py) and m2/wt or m2/m2: S: 5.22 (1.16–23.56)d Postmenopausal women only Ambrosone et al. (6), 1995 
CYP1A1 m1, m2, m3 Caucasian and A-A 30/183 Cauc.; 21/86 A-A Cauc.: m1:m1/m1: 0/2.7 wt/wt: 73.3/79.8 m2:m2/m2: 0/1.1 wt/wt: 82.8/82.9 A-A: m1:m1/m1: 19.0/3.5 wt/wt: 33.4/60.0 m2:m2/wt: 0/6.0 wt/wt: 100/94.0 m3:m3/wt: 19.0/16.2 wt/wt: 81.0/83.7 S m1/m1 in A-A: 9.7 (2.0–47.9)  Taioli et al. (165), 1995 
CYP1A1 m1, m2, m3, m4 Caucasian and A-A 164/164 Cauc.; 59/59 A-A Cauc.: m1:m1/m1: 2.4/3.0 wt/wt: 79.3/84.0 m2:m2/wt: 9.1/7.4 wt/wt: 90.9/92.6 m4:m4/m4: 0.6/0.6 wt/wt: 93.3/92.0 A-A: m1:m1/m1: 3.4/5.1 wt/wt: 71.1/55.9 m2:m2/wt: 1.7/0 wt/wt: 98.3/100 m3:m3/m3: 1.7/0 wt/wt: 79.7/76.3 m4:m4/wt: 1.7/0 wt/wt: 98.3/100 NS Cauc: m1: 1.37 (0.78–2.41) m2: 1.38 (0.62–3.11) m4: 0.82 (0.36–1.90) A-A: m1: 0.51 (0.24–1.10) m2: 1.02 (0.98–1.05) m3: 0.82 (0.34–1.96) m4: 1.02 (0.98–1.05)  Bailey et al. (43), 1998 
CYP1A1 m1, m2 United States registered nurses 466/466 m1:m1/m1 or m1/wt: 18.7/17.2 wt/wt: 81.3/82.8 m2:m2/m2 or m2/wt: 13.1/14.0 wt/wt: 86.9/86 NS RR (m1): 1.05 (0.74–1.50) RR (m2): 0.88 (0.58–1.33) Prospective study nested within “Nurses’ Health Study” Suggested increased risk for early smoking and m1 or m2 Ishibe et al. (166), 1998 
CYP1A1 m2 Postmenopausal women in United States 154/192 m2/m2: 83/88 wt/m2 or wt/wt: 17/12 NS m2/m2 and m2/wt vs. wt/wt 1.79 (0.91–3.55)d but for women with serum PCBe levels above median of distribution in control group: S: m2/m2 or m2/wt: 2.93 (1.17–7.36)d Patients are subset of another study [Ambrosone et al. (6), 1995] Moysich et al. (167), 1999 
Study no.GeneMutation/alleleCountry/ethnicityaCases/controlsb (n)Genotype frequency (% cases/controls)Significancec OR (95% CI)CommentsReferences
CYP1A1 m2 Caucasian  96/126 Allele frequency m2: 0.01/0 NS  Rebbeck et al. (164), 1994 
CYP1A1 m2 United States Caucasian 216/282 m2/m2: 2/1 wt/wt: 80/85 NS m2/m2 and m2/wt vs. wt/wt 1.61 (0.94–2.75)d but for light smokers (up to 29 py) and m2/wt or m2/m2: S: 5.22 (1.16–23.56)d Postmenopausal women only Ambrosone et al. (6), 1995 
CYP1A1 m1, m2, m3 Caucasian and A-A 30/183 Cauc.; 21/86 A-A Cauc.: m1:m1/m1: 0/2.7 wt/wt: 73.3/79.8 m2:m2/m2: 0/1.1 wt/wt: 82.8/82.9 A-A: m1:m1/m1: 19.0/3.5 wt/wt: 33.4/60.0 m2:m2/wt: 0/6.0 wt/wt: 100/94.0 m3:m3/wt: 19.0/16.2 wt/wt: 81.0/83.7 S m1/m1 in A-A: 9.7 (2.0–47.9)  Taioli et al. (165), 1995 
CYP1A1 m1, m2, m3, m4 Caucasian and A-A 164/164 Cauc.; 59/59 A-A Cauc.: m1:m1/m1: 2.4/3.0 wt/wt: 79.3/84.0 m2:m2/wt: 9.1/7.4 wt/wt: 90.9/92.6 m4:m4/m4: 0.6/0.6 wt/wt: 93.3/92.0 A-A: m1:m1/m1: 3.4/5.1 wt/wt: 71.1/55.9 m2:m2/wt: 1.7/0 wt/wt: 98.3/100 m3:m3/m3: 1.7/0 wt/wt: 79.7/76.3 m4:m4/wt: 1.7/0 wt/wt: 98.3/100 NS Cauc: m1: 1.37 (0.78–2.41) m2: 1.38 (0.62–3.11) m4: 0.82 (0.36–1.90) A-A: m1: 0.51 (0.24–1.10) m2: 1.02 (0.98–1.05) m3: 0.82 (0.34–1.96) m4: 1.02 (0.98–1.05)  Bailey et al. (43), 1998 
CYP1A1 m1, m2 United States registered nurses 466/466 m1:m1/m1 or m1/wt: 18.7/17.2 wt/wt: 81.3/82.8 m2:m2/m2 or m2/wt: 13.1/14.0 wt/wt: 86.9/86 NS RR (m1): 1.05 (0.74–1.50) RR (m2): 0.88 (0.58–1.33) Prospective study nested within “Nurses’ Health Study” Suggested increased risk for early smoking and m1 or m2 Ishibe et al. (166), 1998 
CYP1A1 m2 Postmenopausal women in United States 154/192 m2/m2: 83/88 wt/m2 or wt/wt: 17/12 NS m2/m2 and m2/wt vs. wt/wt 1.79 (0.91–3.55)d but for women with serum PCBe levels above median of distribution in control group: S: m2/m2 or m2/wt: 2.93 (1.17–7.36)d Patients are subset of another study [Ambrosone et al. (6), 1995] Moysich et al. (167), 1999 
Table 6A

Continued

Study no.GeneMutation/alleleCountry/ethnicityaCases/controlsb (n)Genotype frequency (% cases/controls)Significancec OR (95% CI)CommentsReferences
CYP1B1 Val432Leu (m1) Asn453Ser (m2) Caucasians, A-A 164/164 Cauc. 59/59 A-A Cauc.: codon 432: leu/leu: 31.7/29.9 val/val: 16.5/11.6 codon 453: ser/ser: 3.0/2.4 asn/asn: 67.7/67.7 A-A: codon 432: leu/leu: 8.4/5.1 val/val: 45.8/44.1 codon 453: asn/ser: 5.1/6.8 asn/asn: 94.9/93.2 NS Cauc: codon 432: val/leu vs. val/val: RR, 0.6 (0.3–1.3)dleu/leu vs. val/val: RR, 0.7 (0.4–1.5)d codon 453: asn/ser vs. asn/asn RR, 0.9 (0.6–1.6)dser/ser vs. asn/asn RR, 1.3 (0.3–4.8)d A-A: codon 432: val/leu vs. val/val: RR, 0.9 (0.4–1.8)dleu vs. val/val: RR, 1.6 (0.4–2.9)d codon 453: asn/ser vs. asn/asn RR, 0.7 (0.2–3.4)d Caucasian patients with codon 432 val/val genotype have more estrogen receptor-positive and progesterone receptor-positive breast cancers Bailey et al. (51), 1998 
CYP2D6 *3,*4,*5 United States Caucasian 167/114 m/m: 7.2/6.1 wt/wt: 62.3/69.3 NS  Buchert et al. (168), 1993 
CYP2D6 *3,*4, *9 Spanish 151/187 PMs: 2.7/3.8 HEM: 31.0/19.9 EM: 65.2/77.4 S HEM 1.81 (1.06–3.11) also: *4/wt and*4/*4 1.7 (1.14–3.13) *3 and*4 are non-functioning *9 and wt are functioning alleles*4 allele most prevalent in postmenopausal women and those with non-ductal-infiltrating carcinomas Ladona et al. (169), 1996 
10 CYP2E1 DraCaucasians 166/221 DC and CC: 13.3/14.0 DD: 86.7/86.0 NS C/C and D/C vs. D/D premenopausal women: 1.04 (0.48–2.24)d postmenopausal women: 1.01 (0.55–1.84)d but C/C and CD in premenopausal smokers: S: 11.1 (1.5–81.4)  Shields et al. (170), 1996 
11 CYP17 A2 Women from Hawaii and Los Angeles; A-A, Latino, Japanese 174/285 A2/A2 and A2/A1: 71.8/66.3 A1/A1: 28.2/33.7 NS 1.32 (0.87–2.00)d but A2/A2 and A2/A1 and regional/metastatic disease: S: 2.5 (1.07–5.94) A1/A1 genotype had lower age at menarche Feigelson et al. (171), 1997 
12 CYP17 A2 Women from East Anglia 835/591 A2/A2: 15.6/14.4 A1/A1: 36.3/38.7 NS OR for A2 allele carriers 1.1 (0.89–1.37)  Dunning et al. (172), 1998 
13 CYP17 A2 Primarily Americans of European descent 109/113 A2/A2: 19.2/15.9 A1/A1: 37.6/32.7 NS A2/A1 vs. A1/A1 0.61 (0.33–1.14) A2/A2 vs. A1/A1 0.89 (0.41–1.95)  Helzlsouer et al. (173), 1996 
14 CYP17 A2 Women in New York City: 224 Caucasian 55 A-A 84 Hispanic 123/240 (76/148 Cauc.; 20/35 A-A; 27/57 Hispanic) A2/A2: 17/15 A1/A1: 37/38 NS  Weston et al. (174), 1998 
15 CYP17 A2 United States registered nurses 463/618 A2/A2: 16/15 A1/A1: 38/35 NS OR for A2 allele carriers: 0.85 (0.65–1.12) Case-control study nested within Nurses’ Health Study Haiman et al. (175), 1999 
Study no.GeneMutation/alleleCountry/ethnicityaCases/controlsb (n)Genotype frequency (% cases/controls)Significancec OR (95% CI)CommentsReferences
CYP1B1 Val432Leu (m1) Asn453Ser (m2) Caucasians, A-A 164/164 Cauc. 59/59 A-A Cauc.: codon 432: leu/leu: 31.7/29.9 val/val: 16.5/11.6 codon 453: ser/ser: 3.0/2.4 asn/asn: 67.7/67.7 A-A: codon 432: leu/leu: 8.4/5.1 val/val: 45.8/44.1 codon 453: asn/ser: 5.1/6.8 asn/asn: 94.9/93.2 NS Cauc: codon 432: val/leu vs. val/val: RR, 0.6 (0.3–1.3)dleu/leu vs. val/val: RR, 0.7 (0.4–1.5)d codon 453: asn/ser vs. asn/asn RR, 0.9 (0.6–1.6)dser/ser vs. asn/asn RR, 1.3 (0.3–4.8)d A-A: codon 432: val/leu vs. val/val: RR, 0.9 (0.4–1.8)dleu vs. val/val: RR, 1.6 (0.4–2.9)d codon 453: asn/ser vs. asn/asn RR, 0.7 (0.2–3.4)d Caucasian patients with codon 432 val/val genotype have more estrogen receptor-positive and progesterone receptor-positive breast cancers Bailey et al. (51), 1998 
CYP2D6 *3,*4,*5 United States Caucasian 167/114 m/m: 7.2/6.1 wt/wt: 62.3/69.3 NS  Buchert et al. (168), 1993 
CYP2D6 *3,*4, *9 Spanish 151/187 PMs: 2.7/3.8 HEM: 31.0/19.9 EM: 65.2/77.4 S HEM 1.81 (1.06–3.11) also: *4/wt and*4/*4 1.7 (1.14–3.13) *3 and*4 are non-functioning *9 and wt are functioning alleles*4 allele most prevalent in postmenopausal women and those with non-ductal-infiltrating carcinomas Ladona et al. (169), 1996 
10 CYP2E1 DraCaucasians 166/221 DC and CC: 13.3/14.0 DD: 86.7/86.0 NS C/C and D/C vs. D/D premenopausal women: 1.04 (0.48–2.24)d postmenopausal women: 1.01 (0.55–1.84)d but C/C and CD in premenopausal smokers: S: 11.1 (1.5–81.4)  Shields et al. (170), 1996 
11 CYP17 A2 Women from Hawaii and Los Angeles; A-A, Latino, Japanese 174/285 A2/A2 and A2/A1: 71.8/66.3 A1/A1: 28.2/33.7 NS 1.32 (0.87–2.00)d but A2/A2 and A2/A1 and regional/metastatic disease: S: 2.5 (1.07–5.94) A1/A1 genotype had lower age at menarche Feigelson et al. (171), 1997 
12 CYP17 A2 Women from East Anglia 835/591 A2/A2: 15.6/14.4 A1/A1: 36.3/38.7 NS OR for A2 allele carriers 1.1 (0.89–1.37)  Dunning et al. (172), 1998 
13 CYP17 A2 Primarily Americans of European descent 109/113 A2/A2: 19.2/15.9 A1/A1: 37.6/32.7 NS A2/A1 vs. A1/A1 0.61 (0.33–1.14) A2/A2 vs. A1/A1 0.89 (0.41–1.95)  Helzlsouer et al. (173), 1996 
14 CYP17 A2 Women in New York City: 224 Caucasian 55 A-A 84 Hispanic 123/240 (76/148 Cauc.; 20/35 A-A; 27/57 Hispanic) A2/A2: 17/15 A1/A1: 37/38 NS  Weston et al. (174), 1998 
15 CYP17 A2 United States registered nurses 463/618 A2/A2: 16/15 A1/A1: 38/35 NS OR for A2 allele carriers: 0.85 (0.65–1.12) Case-control study nested within Nurses’ Health Study Haiman et al. (175), 1999 
Table 6B

Continued

Study no.GeneMutation/alleleCountry/ethnicityaCases/controlsb (n)Genotype frequency (% cases/controls)Significancec OR (95% CI)CommentsReferences
16 CYP19 TTTA repeat (intron 5), alleles found with 7, 8, 9, 11, and 12 repeats Swedish and Norwegian 182 sporadic and 185 familial cases, 252 controls Allele frequencies: A1 (7xTTTA): 0.037/0.016 A2 (8xTTTA): 0.339/0.329 A3 (9xTTTA): 0.011/0.014 A4 (11xTTTA): 0.091/0.119 A5 (12xTTTA): 0.522/0.522 S A1 allele carriers and breast cancer: 2.42 (1.03–5.80) Higher frequency of A1 allele in patients with estrogen/progesterone receptor-positive tumors Kristensen et al. (176), 1998 
17 CYP19 6 common and 2 rare alleles United States Caucasians 348/145 171-bp allele homozygotes: 3.78/0.70 Allele frequencies: A1 (168 bp): 0.327/0.334 A2 (171 bp): 0.185/0.134 A3 (175 bp): 0.118/0.116 A4 (183 bp): 0.019/0.018 A5 (187 bp): 0.335/0.345 A6 (191 bp): 0.016/0.053 S 171-bp allele overrepresented in cases RR, 5.4; P = 0.019  Siegelmann Danieli and Buetow (177), 1999 
Study no.GeneMutation/alleleCountry/ethnicityaCases/controlsb (n)Genotype frequency (% cases/controls)Significancec OR (95% CI)CommentsReferences
16 CYP19 TTTA repeat (intron 5), alleles found with 7, 8, 9, 11, and 12 repeats Swedish and Norwegian 182 sporadic and 185 familial cases, 252 controls Allele frequencies: A1 (7xTTTA): 0.037/0.016 A2 (8xTTTA): 0.339/0.329 A3 (9xTTTA): 0.011/0.014 A4 (11xTTTA): 0.091/0.119 A5 (12xTTTA): 0.522/0.522 S A1 allele carriers and breast cancer: 2.42 (1.03–5.80) Higher frequency of A1 allele in patients with estrogen/progesterone receptor-positive tumors Kristensen et al. (176), 1998 
17 CYP19 6 common and 2 rare alleles United States Caucasians 348/145 171-bp allele homozygotes: 3.78/0.70 Allele frequencies: A1 (168 bp): 0.327/0.334 A2 (171 bp): 0.185/0.134 A3 (175 bp): 0.118/0.116 A4 (183 bp): 0.019/0.018 A5 (187 bp): 0.335/0.345 A6 (191 bp): 0.016/0.053 S 171-bp allele overrepresented in cases RR, 5.4; P = 0.019  Siegelmann Danieli and Buetow (177), 1999 
a

A-A, African-American.

b

Cauc., Caucasian.

c

NS, not significant; S, significant; RR,relative risk.

d

Data adjusted for confounding factors such as smoking, age, gender, and others (for details, refer to original publication).

e

PCB, polychlorinated biphenyl.

Table 7

CYPs and lung cancer

Study no.GeneMutation/alleleMajor cancer subtypesa(n)Country/ethnicityCases/controls (n)Genotype frequenciesb (% cases/controls)Significancec OR (95% CI)CommentsReferences
CYP2A6 *2, *3 Not specified United States population 182/460 mut/mut: 1.1/2.4 wt/wt: 78.0/77.2 NS RR, 1 variant allele: 1.0 (0.6–1.6) 2 variant alleles: 0.5 (0.1–2.1)  London et al. (55), 1999 
CYP2D6 *4 SCC (145) AC (74) SCLC (52) English Caucasians 361/720 PM: 3.6/4.3 EM: 64.8/66.1 NS P = 0.9 Effect on LCd risk not modified by histological type. Smith et al. (116), 1992; study population overlapping with Wolf et al. (117), 1992 
CYP2D6 *3,*4,*5 SCC (58) AC (36) Finnish Caucasians 106/122 PM: 0.9/5.7 HEM+ EM: 99.1/94.3 S EM: 6.4 (1.0–143) Effect on LC risk not modified by amount of smoking or histological type. Hirvonen et al. (93), 1993; study population overlapping with Hirvonen et al. (118), 1993 
CYP2D6 *3,*4,*9 Epidermoid (48) AC (20) Microcytic (15) Spanish Caucasians  89/98 PM: 3/8 (*9 allele incl) PM: 0/7 (*9 not incl) HEM: 36/24 EM: 61/68 S P < 0.02 if*9 allele not included as PM *9 allele does not abolish CYP2D6 activity completely. Agundez et al. (119), 1994 
CYP2D6 *3,*4,*5,*7 SCC (74) SCLC (72) AC (38) LCLC (22) Norwegian Caucasians 218/289 PM: 9.8/5.1 EM: 60.8/59.0 (*7 not included in genotype frequencies) NS P = 0.22 Effect on LC risk not modified by amount of smoking or histological type. Tefre et al. (120), 1994 
CYP2D6 *3,*4 SCC (84) SCLC (50) LCLC (33) AC (33) Slovenian Caucasians 200/107 PM: 2.5/6.5 HEM: 27/31 EM: 70.5/62.5 S P = 0.056 Effect on LC risk not modified by histological type. Dolzan et al. (121), 1995 
CYP2D6 *3,*4,*5 AC (27) SCC (23) United States population  54/50 PM: 7.4/16 EM: 37/50 NS EM+ HEM: 2.4 (0.6–10.2) CYP2E1, GSTM1, GSTT1 combination NS El Zein et al. (122), 1997; study population overlapping with El Zein et al. (123), 1997 
CYP2D6 *3,*4,*5, *16,*2xn AC (121) SCC (82) SCLC (46) United States Caucasians and A-A 341/710 PM: all: 4.4/4.9 (Cauc.: 5.9/5.8; A-A: 2.5/3.3) EM: 71.4/65.2 UM: 5.2/4.5 (Cauc.: 4.9/4.3; A-A: 5.7/4.9) NS Cauc.: PM: 1.0 (0.4–2.3)e A-A: PM: 0.7 (0.2–2.2)e but AC: for UMs in A-A: S: 3.6 (1.1–11.7)e Effect on LC risk not modified by smoking, asbestos, or PAH exposure or histological type. London et al. (124), 1997 
CYP2D6 SSCP >40 mutations detected SCC (115) AC (58) SCLC (49) French Caucasians 249/265 PM: 8.0/8.4 HEM+ EM: 89/90 UM: 3.0/1.6 NS but*1A/*2 genotype significantly associated with LC, especially SCLC: S: 3.6 (1.1–11.9)e  Legrand Andreoletti et al. (63), 1998; study population overlapping with Legrand et al. (125), 1996 and Stücker et al. (126), 1995 
10 CYP2D6 *3,*4,*5,*6A,*9,*10 A AC (35) SCLC (30) SCC (16) Canadian Caucasians  98/110 PM: 7.1/2.7 EM: 54.1/57.3 NS HEM: 0.3 (0.05–1.6)e EM: 0.3 (0.05–1.5)e  Shaw et al. (127), 1998; study population overlapping with Shaw et al. (128), 1997 
11 CYP2E1 DraSCC (14) AC (14) SCLC (13) Not defined  47/56 CC: 0/10.7 CD: 46.8/30.4 DD: 53.2/59.9 S P < 0.05  Uematsu et al. (129), 1991; study population may overlap with Uematsu et al. (130), 1992 and (131), 1994 
Study no.GeneMutation/alleleMajor cancer subtypesa(n)Country/ethnicityCases/controls (n)Genotype frequenciesb (% cases/controls)Significancec OR (95% CI)CommentsReferences
CYP2A6 *2, *3 Not specified United States population 182/460 mut/mut: 1.1/2.4 wt/wt: 78.0/77.2 NS RR, 1 variant allele: 1.0 (0.6–1.6) 2 variant alleles: 0.5 (0.1–2.1)  London et al. (55), 1999 
CYP2D6 *4 SCC (145) AC (74) SCLC (52) English Caucasians 361/720 PM: 3.6/4.3 EM: 64.8/66.1 NS P = 0.9 Effect on LCd risk not modified by histological type. Smith et al. (116), 1992; study population overlapping with Wolf et al. (117), 1992 
CYP2D6 *3,*4,*5 SCC (58) AC (36) Finnish Caucasians 106/122 PM: 0.9/5.7 HEM+ EM: 99.1/94.3 S EM: 6.4 (1.0–143) Effect on LC risk not modified by amount of smoking or histological type. Hirvonen et al. (93), 1993; study population overlapping with Hirvonen et al. (118), 1993 
CYP2D6 *3,*4,*9 Epidermoid (48) AC (20) Microcytic (15) Spanish Caucasians  89/98 PM: 3/8 (*9 allele incl) PM: 0/7 (*9 not incl) HEM: 36/24 EM: 61/68 S P < 0.02 if*9 allele not included as PM *9 allele does not abolish CYP2D6 activity completely. Agundez et al. (119), 1994 
CYP2D6 *3,*4,*5,*7 SCC (74) SCLC (72) AC (38) LCLC (22) Norwegian Caucasians 218/289 PM: 9.8/5.1 EM: 60.8/59.0 (*7 not included in genotype frequencies) NS P = 0.22 Effect on LC risk not modified by amount of smoking or histological type. Tefre et al. (120), 1994 
CYP2D6 *3,*4 SCC (84) SCLC (50) LCLC (33) AC (33) Slovenian Caucasians 200/107 PM: 2.5/6.5 HEM: 27/31 EM: 70.5/62.5 S P = 0.056 Effect on LC risk not modified by histological type. Dolzan et al. (121), 1995 
CYP2D6 *3,*4,*5 AC (27) SCC (23) United States population  54/50 PM: 7.4/16 EM: 37/50 NS EM+ HEM: 2.4 (0.6–10.2) CYP2E1, GSTM1, GSTT1 combination NS El Zein et al. (122), 1997; study population overlapping with El Zein et al. (123), 1997 
CYP2D6 *3,*4,*5, *16,*2xn AC (121) SCC (82) SCLC (46) United States Caucasians and A-A 341/710 PM: all: 4.4/4.9 (Cauc.: 5.9/5.8; A-A: 2.5/3.3) EM: 71.4/65.2 UM: 5.2/4.5 (Cauc.: 4.9/4.3; A-A: 5.7/4.9) NS Cauc.: PM: 1.0 (0.4–2.3)e A-A: PM: 0.7 (0.2–2.2)e but AC: for UMs in A-A: S: 3.6 (1.1–11.7)e Effect on LC risk not modified by smoking, asbestos, or PAH exposure or histological type. London et al. (124), 1997 
CYP2D6 SSCP >40 mutations detected SCC (115) AC (58) SCLC (49) French Caucasians 249/265 PM: 8.0/8.4 HEM+ EM: 89/90 UM: 3.0/1.6 NS but*1A/*2 genotype significantly associated with LC, especially SCLC: S: 3.6 (1.1–11.9)e  Legrand Andreoletti et al. (63), 1998; study population overlapping with Legrand et al. (125), 1996 and Stücker et al. (126), 1995 
10 CYP2D6 *3,*4,*5,*6A,*9,*10 A AC (35) SCLC (30) SCC (16) Canadian Caucasians  98/110 PM: 7.1/2.7 EM: 54.1/57.3 NS HEM: 0.3 (0.05–1.6)e EM: 0.3 (0.05–1.5)e  Shaw et al. (127), 1998; study population overlapping with Shaw et al. (128), 1997 
11 CYP2E1 DraSCC (14) AC (14) SCLC (13) Not defined  47/56 CC: 0/10.7 CD: 46.8/30.4 DD: 53.2/59.9 S P < 0.05  Uematsu et al. (129), 1991; study population may overlap with Uematsu et al. (130), 1992 and (131), 1994 
Table 7A

Continued

Study no.GeneMutation/alleleMajor cancer subtypesa(n)Country/ethnicityCases/controls (n)Genotype frequenciesb (% cases/controls)Significancec OR (95% CI)CommentsReferences
12 CYP2E1 PstI RsaSCC (31) AC (19) United States Caucasians and A-A  67/61 PstI c2c2: 0/0 c1c1: 96/92 NS PstI c1c2: 0.7 (0.2–5.4) RsaI c1c2: 0.9 (0.2–2.8) 20 controls had other cancers; effect on LC risk not modified by race or histological type. Kato et al. (132), 1992 
13 CYP2E1 DraSCC (23) AC (25) SCLC (10) LCLC (10) Not defined  74/73 CC: 2.7/13.7 CD: 45.9/28.8 DD: 51.4/57.5 S P < 0.05  Uematsu et al. (130), 1992; study population may overlap with Uematsu et al. (129), 1991 and (131), 1994 
14 CYP2E1 DraI, RsaSCC (54) AC (35) Finnish Caucasians 101/121 DraI: CC: 2.0/0.8 DD: 84.2/79.3 RsaI: allele frequency: c2 = 0.02/0.012 NS P = 0.44 Effect on LC risk not modified by smoking or histological type. Hirvonen et al. (133), 1993 
15 CYP2E1 DraI, TaqI, RsaSCC AC (27) SCLC LCLC Swedish Caucasians 195/206 DraI: CC: 0/1 DD: 83/81 TaqI: A1A1: 0/0.5 A2A2: 81/81 RsaI: c2c2: 0/0.5 c1c1: 96/90 NS but allele frequency of c2 (c2 = 0.02/0.05) significantly lower among cases than controls  Persson et al. (134), 1993 
16 CYP2E1 DraSCC (24) AC (36) SCLC (21) LCLC (10) Not defined  91/76 CC: 2.2/14.5 CD: 46.2/28.9 DD: 51.6/56.6 S CC: 0.13 (0.04–0.51) but: CD: 2.1 (1.1–4.0) Effect on LC risk not modified by histological type. Uematsu et al. (131), 1994; study population may overlap with Uematsu et al. (129), 1991 and (130), 1992 
17 CYP2E1 DraSCC (31) AC (19) United States Caucasians and A-A  58/56 CC: 0/0 DD: 79/86 NS CD: 1.6 (0.6–4.2)e Same population as Kato et al. (132), 1992. 18 controls had other cancers. Effect on LC risk not modified by histological type; A-A and Cauc. had similar allele frequencies. Kato et al. (135), 1994 
18 CYP2E1 RsaAC (143) SCC (104) SCLC (51) Japanese 316/503 c2c2: 4.1/3.2 c1c1: 65.5/63.0 NS Effect on LC risk not modified by smoking, alcohol consumption or histological type. Watanabe et al. (136), 1995 
19 CYP2E1 RsaNot specified Brazilians  99/108 c2c2: 0/0 c1c1: 90/89 NS c1c2: 0.9 (0.4–2.1)e Effect on LC risk not modified by histological type. Hamada et al. (100), 1995; study population overlapping with Sugimura et al. (99), 1995 
20 CYP2E1 RsaAC (121) SCC (82) SCLC (44) United States Caucasians and A-A 341/706 A-A: 157/247 Cauc.: 184/459 c2c2: 0% for all A-A: c1c1: 98.1/98.0 Cauc.: c1c1: 94.6/92.2 NS c1c2: 0.7 (0.4–1.5)e Effect on LC risk not modified by histological type, asbestos exposure, vitamins, or dietary intake. No racial difference. London et al. (137), 1996 
Study no.GeneMutation/alleleMajor cancer subtypesa(n)Country/ethnicityCases/controls (n)Genotype frequenciesb (% cases/controls)Significancec OR (95% CI)CommentsReferences
12 CYP2E1 PstI RsaSCC (31) AC (19) United States Caucasians and A-A  67/61 PstI c2c2: 0/0 c1c1: 96/92 NS PstI c1c2: 0.7 (0.2–5.4) RsaI c1c2: 0.9 (0.2–2.8) 20 controls had other cancers; effect on LC risk not modified by race or histological type. Kato et al. (132), 1992 
13 CYP2E1 DraSCC (23) AC (25) SCLC (10) LCLC (10) Not defined  74/73 CC: 2.7/13.7 CD: 45.9/28.8 DD: 51.4/57.5 S P < 0.05  Uematsu et al. (130), 1992; study population may overlap with Uematsu et al. (129), 1991 and (131), 1994 
14 CYP2E1 DraI, RsaSCC (54) AC (35) Finnish Caucasians 101/121 DraI: CC: 2.0/0.8 DD: 84.2/79.3 RsaI: allele frequency: c2 = 0.02/0.012 NS P = 0.44 Effect on LC risk not modified by smoking or histological type. Hirvonen et al. (133), 1993 
15 CYP2E1 DraI, TaqI, RsaSCC AC (27) SCLC LCLC Swedish Caucasians 195/206 DraI: CC: 0/1 DD: 83/81 TaqI: A1A1: 0/0.5 A2A2: 81/81 RsaI: c2c2: 0/0.5 c1c1: 96/90 NS but allele frequency of c2 (c2 = 0.02/0.05) significantly lower among cases than controls  Persson et al. (134), 1993 
16 CYP2E1 DraSCC (24) AC (36) SCLC (21) LCLC (10) Not defined  91/76 CC: 2.2/14.5 CD: 46.2/28.9 DD: 51.6/56.6 S CC: 0.13 (0.04–0.51) but: CD: 2.1 (1.1–4.0) Effect on LC risk not modified by histological type. Uematsu et al. (131), 1994; study population may overlap with Uematsu et al. (129), 1991 and (130), 1992 
17 CYP2E1 DraSCC (31) AC (19) United States Caucasians and A-A  58/56 CC: 0/0 DD: 79/86 NS CD: 1.6 (0.6–4.2)e Same population as Kato et al. (132), 1992. 18 controls had other cancers. Effect on LC risk not modified by histological type; A-A and Cauc. had similar allele frequencies. Kato et al. (135), 1994 
18 CYP2E1 RsaAC (143) SCC (104) SCLC (51) Japanese 316/503 c2c2: 4.1/3.2 c1c1: 65.5/63.0 NS Effect on LC risk not modified by smoking, alcohol consumption or histological type. Watanabe et al. (136), 1995 
19 CYP2E1 RsaNot specified Brazilians  99/108 c2c2: 0/0 c1c1: 90/89 NS c1c2: 0.9 (0.4–2.1)e Effect on LC risk not modified by histological type. Hamada et al. (100), 1995; study population overlapping with Sugimura et al. (99), 1995 
20 CYP2E1 RsaAC (121) SCC (82) SCLC (44) United States Caucasians and A-A 341/706 A-A: 157/247 Cauc.: 184/459 c2c2: 0% for all A-A: c1c1: 98.1/98.0 Cauc.: c1c1: 94.6/92.2 NS c1c2: 0.7 (0.4–1.5)e Effect on LC risk not modified by histological type, asbestos exposure, vitamins, or dietary intake. No racial difference. London et al. (137), 1996 
Table 7B

Continued

Study no.GeneMutation/alleleMajor cancer subtypesa (n)Country/ethnicityCases/controls (n)Genotype frequenciesb (% cases/controls)Significancec OR (95% CI)CommentsReferences
21 CYP2E1 PstAC (73) SCC (53) Japanese 126/612 c2c2: 5.6/4.1 c1c1: 69.0/63.9 NS c2c2: 1.4 (0.6–3.3) borderline for SCC: c2c2: 2.5 (0.9–6.5) c2c2 genotype correlated positively with p53 mutations. Oyama et al. (138), 1997 
22 CYP2E1 PstSCC (23) AC (27) United States population 54/50 all smokers c2c2: 1.9/0.0 c1c1: 87/94 NS but c1c2+ c2c2 vs c1c1 AC: S: 18.9 (1.0–351) Small number of subjects El Zein et al. (122), 1997; study population overlapping with El Zein et al. (139), 1997 
23 CYP2E1 PstNot specified M-A and A-A 137/206 A-A: 92/144 M-A: 45/92 All: c2c2: 0.7/1.0 c1c2: 11/19.4 c1c1: 88.3/79.6 M-A: c2c2: 2.2/1.1 c1c2: 11.1/28.2 c1c1: 86.7/70.7 A-A: c2c2: 0/0.9 c1c1: 89.1/86.8 S only for M-A: c1c1 vs. c1c2+ c2c2; M-A 14.0 (1.9–102)e M-A males: 15.0 (1.9–121)ec1c1+ smoking: 16.3 (2.1–127)e Cancer at earlier age in c1c1 patients. c1c1 not associated with LC among A-A, nonsmokers, or women. Wu et al. (140), 1997 
24 CYP2E1 DraNot specified M-A and A-A 126/193 A-A: 85/104 M-A: 41/89 All: CC: 0.8/2.1 CD: 12.7/23.3 DD: 86.5/74.6 M-A: CC: 2.4/3.4 DD: 78.1/69.6 A-A: CC: 0.0/1.0 DD: 90.6/78.8 S All (DD vs. CD+ CC): 2.4 (1.1–5.3)e Men (DD vs. CD + CC): 3.4 (1.3–8.7)e DD+ smokers: 22.7 (3.0–174.6)e Same population as Wu et al. (140), 1997. Combined smoking and DD genotoxic effect greater than multiplicative (OR, 22.7). DD not associated with LC among nonsmokers or women. Wu et al. (141), 1998 
25 CYP2E1 DraI, RsaSCC (74) AC (162) SCLC (51) Caucasians, Hawaians, and Japanese 341/456 DraI: CC: 1.5/5.5 CD: 27.5/26.8 DD: 71/67.7 RsaI: c2c2: 0.6/3.1 c1/c2: 19.6/22.5 c1c1: 79.8/74.4 S DraI all LC: CC: 0.2 (0.1–0.7)eAC:CC: 0.1 (0.0–0.5)e RsaI: c2c2: 0.1 (0.0–0.5)e Ethnic groups not studied separately. Le Marchand et al. (109), 1998 
26 CYP2E1 DraI, RsaAC (38) SCLC (18) SCC (14) Chinese  76/122 DraI: CC: 6.6/4.9 DD: 61.8/48.4 RsaI: c2c2: 2.6/4.9 c1c1: 63.2/51.6 NS *5/*5: 0.5 (0.1–2.1)*6/*6: 1.1 (0.3–3.4)  Persson et al. (114), 1999 
27 CYP2C9 *2 AC (115) SCC (80) SCLC (43) A-A and Caucasians A-A: 152/239 Cauc.: 177/461 A-A:*2/*2+*1/*2: 5.9/7.1 Cauc.:*2/*2+ *1/*2: 28.3/19.3 NS Cauc.:c2: 1.6 (0.96–2.5)e A-A: c2: 1.2 (0.5–3.1)e but AC in Cauc. S c2: 2.0 (1.1–3.8)e Effect on LC risk not modified by histological type. London et al. (142), 1996 
28 CYP2C9 *2,*3 Not specified Caucasians 173/457 *2/*2: 1.7/0.7*3/*3: 0.6/0.0 *1/*1: 63/66.1 NS 1 variant allele: 1.1 (0.7–1.6)e 2 variant alleles: 2.4 (0.8–6.8)e Effect on LC risk not modified by histological type. London et al. (143), 1997 
29 CYP2C19 *2,*3 SCC (14) Japanese 14/64 PM: 42.9/14.1 HEM: 35.7/39 EM: 21.4/46.9 S “risk factor”: PM: 4.6 (1.3–16.4) Very few subjects. Tsuneoka et al. (144), 1996 
Study no.GeneMutation/alleleMajor cancer subtypesa (n)Country/ethnicityCases/controls (n)Genotype frequenciesb (% cases/controls)Significancec OR (95% CI)CommentsReferences
21 CYP2E1 PstAC (73) SCC (53) Japanese 126/612 c2c2: 5.6/4.1 c1c1: 69.0/63.9 NS c2c2: 1.4 (0.6–3.3) borderline for SCC: c2c2: 2.5 (0.9–6.5) c2c2 genotype correlated positively with p53 mutations. Oyama et al. (138), 1997 
22 CYP2E1 PstSCC (23) AC (27) United States population 54/50 all smokers c2c2: 1.9/0.0 c1c1: 87/94 NS but c1c2+ c2c2 vs c1c1 AC: S: 18.9 (1.0–351) Small number of subjects El Zein et al. (122), 1997; study population overlapping with El Zein et al. (139), 1997 
23 CYP2E1 PstNot specified M-A and A-A 137/206 A-A: 92/144 M-A: 45/92 All: c2c2: 0.7/1.0 c1c2: 11/19.4 c1c1: 88.3/79.6 M-A: c2c2: 2.2/1.1 c1c2: 11.1/28.2 c1c1: 86.7/70.7 A-A: c2c2: 0/0.9 c1c1: 89.1/86.8 S only for M-A: c1c1 vs. c1c2+ c2c2; M-A 14.0 (1.9–102)e M-A males: 15.0 (1.9–121)ec1c1+ smoking: 16.3 (2.1–127)e Cancer at earlier age in c1c1 patients. c1c1 not associated with LC among A-A, nonsmokers, or women. Wu et al. (140), 1997 
24 CYP2E1 DraNot specified M-A and A-A 126/193 A-A: 85/104 M-A: 41/89 All: CC: 0.8/2.1 CD: 12.7/23.3 DD: 86.5/74.6 M-A: CC: 2.4/3.4 DD: 78.1/69.6 A-A: CC: 0.0/1.0 DD: 90.6/78.8 S All (DD vs. CD+ CC): 2.4 (1.1–5.3)e Men (DD vs. CD + CC): 3.4 (1.3–8.7)e DD+ smokers: 22.7 (3.0–174.6)e Same population as Wu et al. (140), 1997. Combined smoking and DD genotoxic effect greater than multiplicative (OR, 22.7). DD not associated with LC among nonsmokers or women. Wu et al. (141), 1998 
25 CYP2E1 DraI, RsaSCC (74) AC (162) SCLC (51) Caucasians, Hawaians, and Japanese 341/456 DraI: CC: 1.5/5.5 CD: 27.5/26.8 DD: 71/67.7 RsaI: c2c2: 0.6/3.1 c1/c2: 19.6/22.5 c1c1: 79.8/74.4 S DraI all LC: CC: 0.2 (0.1–0.7)eAC:CC: 0.1 (0.0–0.5)e RsaI: c2c2: 0.1 (0.0–0.5)e Ethnic groups not studied separately. Le Marchand et al. (109), 1998 
26 CYP2E1 DraI, RsaAC (38) SCLC (18) SCC (14) Chinese  76/122 DraI: CC: 6.6/4.9 DD: 61.8/48.4 RsaI: c2c2: 2.6/4.9 c1c1: 63.2/51.6 NS *5/*5: 0.5 (0.1–2.1)*6/*6: 1.1 (0.3–3.4)  Persson et al. (114), 1999 
27 CYP2C9 *2 AC (115) SCC (80) SCLC (43) A-A and Caucasians A-A: 152/239 Cauc.: 177/461 A-A:*2/*2+*1/*2: 5.9/7.1 Cauc.:*2/*2+ *1/*2: 28.3/19.3 NS Cauc.:c2: 1.6 (0.96–2.5)e A-A: c2: 1.2 (0.5–3.1)e but AC in Cauc. S c2: 2.0 (1.1–3.8)e Effect on LC risk not modified by histological type. London et al. (142), 1996 
28 CYP2C9 *2,*3 Not specified Caucasians 173/457 *2/*2: 1.7/0.7*3/*3: 0.6/0.0 *1/*1: 63/66.1 NS 1 variant allele: 1.1 (0.7–1.6)e 2 variant alleles: 2.4 (0.8–6.8)e Effect on LC risk not modified by histological type. London et al. (143), 1997 
29 CYP2C19 *2,*3 SCC (14) Japanese 14/64 PM: 42.9/14.1 HEM: 35.7/39 EM: 21.4/46.9 S “risk factor”: PM: 4.6 (1.3–16.4) Very few subjects. Tsuneoka et al. (144), 1996 
a

SCC, squamous cell carcinoma; AC,adenocarcinoma; SCLC, small cell lung cancer; LCLC, large cell lung cancer.

b

mut, mutation; wt, wild type; Cauc.,Caucasian; A-A, African-American; M-A, Mexican-American.

c

NS, not significant; S, significant; RR,relative risk.

d

LC, lung cancer.

e

Data adjusted for confounding factors such as smoking, age, gender, and others (for details, refer to original publication).

Table 8

Modulation of bulky DNA adducts by CYP1A1/GSTM1 genotypes in smokers’ tissue and leukocytes

Study no.EthnicityPY or cig/dayaDetection methodCYP1A1/GSTM1 combinationSubjects (n)Adduct levels (per 108 nucleotides)Effect and significanceReferences
Present (n)Mean ± SD or range
I. Lung parenchyma and bronchus          
Russian Caucasian 10–40 cig/day HPLC/fdb wt/wt-GSTM1 active (A11 <0.2c A vs. C P < 0.001 Rojas et al. (39), 1998 
    wt/m1 (m2)-GSTM1 active (B<0.2 B vs. D P < 0.001  
    wt/wt-GSTM1 0/0 (C0.68± 0.13   
    m1/m1-GSTM1 0/0 (D4.15± 3.18 D vs. C P < 0.01  
Finnish Caucasian 10–20 cig/day 20–40 cig/day HPLC/fd Inducible CYP1A1-GSTM1 0/0 (A122 A vs. B P < 0.001 Bartsch (38), 1996 
    Inducible CYP1A1-GSTM1 active (B<1   
Hungarian Caucasian NA 32wt/wt-GSTM1 active 40 na 8.4± 3.8  Schoket et al. (178), 1998 
    wt/m1 (m1/m1)-GSTM1 active 10 na 9.0± 5.3 NSd  
    wt/wt-GSTM1 0/0 36 na 8.7± 4.4   
    wt/m1 (m1/m1)-GSTM1 0/0 12 na 9.5± 4.1   
II. Leukocytes          
a) Smokers also occupationally exposed to PAH          
Swedish Caucasian NA 32wt/wt 23 23 0.95 (0.60–1.42)  Ichiba et al. (179), 1994 
    wt/m1 0.55 (0.45–0.96) NS  
    GSTM1 active 16 16 0.83 (0.59–1.21)   
    GSTM1 0/0 12 12 0.88 (0.57–1.35)   
French Caucasian 23± 12 cig/day HPLC/fd wt/wt-GSTM1 active (A<0.2 A vs. C P < 0.001 Rojas et al. (180), 2000 
    wt/m1 (m2)-GSTM1 active (B<0.2 B vs. D P < 0.001  
    wt/wt-GSTM1 0/0 (C11 11 2.3 (0.8–3.6)   
    wt/m1 (m2)-GSTM1 0/0 (D2.8 (1.8–6.1) D vs. C NS  
    m1/m1-GSTM1 0/0 44   
b) Smokers not occupationally exposed to PAH          
Swedish Caucasian NA 32wt/wt 0.69 (0.57–1.30)  Ichiba et al. (179), 1994 
    wt/m1 0.7 (–) NS  
    GSTM1 active 0.7 (0.68–1.55)   
    GSTM1 0/0 0.66 (0.39–1.10)   
American Caucasian 39± 23 ELISA wt/wt (A148 NA 4.7± 5.3  Mooney et al. (35), 1997 
    wt/m2 (B10 NA 9.8 ± 8.5 B vs. A P < 0.01  
    wt/wt-GSTM1 active (C78 NA 4.5± 5.8   
    wt/m2-GSTM1 active (DNA 10.5± 7.2  D vs. C P < 0.004  
    wt/wt-GSTM1 0/0 (E70 NA 4.4± 4.7   
    wt/m2-GSTM1 0/0 (FNA  8.7± 11.5   
Polish Caucasian 41± 33 32wt/wt NA NA 3.96± 4.6   Butkiewicz et al. (181), 1998 
    wt/m2 NA NA 5.11± 4.15   
    wt/wt-GSTM1 active NA NA 3.25 ± 3.56 NS  
    wt/m2-active NA NA 0.4 (0.4–0.4)   
    wt/wt-GSTM1 0/0 NA NA 4.80± 5.60   
    wt/m2-GSTM1 0/0 NA NA 6.30± 3.69   
Japanese <20 cig/day 32wt/wt 29 29 1.01± 0.85  Ichiba et al. (182), 1998 
Study no.EthnicityPY or cig/dayaDetection methodCYP1A1/GSTM1 combinationSubjects (n)Adduct levels (per 108 nucleotides)Effect and significanceReferences
Present (n)Mean ± SD or range
I. Lung parenchyma and bronchus          
Russian Caucasian 10–40 cig/day HPLC/fdb wt/wt-GSTM1 active (A11 <0.2c A vs. C P < 0.001 Rojas et al. (39), 1998 
    wt/m1 (m2)-GSTM1 active (B<0.2 B vs. D P < 0.001  
    wt/wt-GSTM1 0/0 (C0.68± 0.13   
    m1/m1-GSTM1 0/0 (D4.15± 3.18 D vs. C P < 0.01  
Finnish Caucasian 10–20 cig/day 20–40 cig/day HPLC/fd Inducible CYP1A1-GSTM1 0/0 (A122 A vs. B P < 0.001 Bartsch (38), 1996 
    Inducible CYP1A1-GSTM1 active (B<1   
Hungarian Caucasian NA 32wt/wt-GSTM1 active 40 na 8.4± 3.8  Schoket et al. (178), 1998 
    wt/m1 (m1/m1)-GSTM1 active 10 na 9.0± 5.3 NSd  
    wt/wt-GSTM1 0/0 36 na 8.7± 4.4   
    wt/m1 (m1/m1)-GSTM1 0/0 12 na 9.5± 4.1   
II. Leukocytes          
a) Smokers also occupationally exposed to PAH          
Swedish Caucasian NA 32wt/wt 23 23 0.95 (0.60–1.42)  Ichiba et al. (179), 1994 
    wt/m1 0.55 (0.45–0.96) NS  
    GSTM1 active 16 16 0.83 (0.59–1.21)   
    GSTM1 0/0 12 12 0.88 (0.57–1.35)   
French Caucasian 23± 12 cig/day HPLC/fd wt/wt-GSTM1 active (A<0.2 A vs. C P < 0.001 Rojas et al. (180), 2000 
    wt/m1 (m2)-GSTM1 active (B<0.2 B vs. D P < 0.001  
    wt/wt-GSTM1 0/0 (C11 11 2.3 (0.8–3.6)   
    wt/m1 (m2)-GSTM1 0/0 (D2.8 (1.8–6.1) D vs. C NS  
    m1/m1-GSTM1 0/0 44   
b) Smokers not occupationally exposed to PAH          
Swedish Caucasian NA 32wt/wt 0.69 (0.57–1.30)  Ichiba et al. (179), 1994 
    wt/m1 0.7 (–) NS  
    GSTM1 active 0.7 (0.68–1.55)   
    GSTM1 0/0 0.66 (0.39–1.10)   
American Caucasian 39± 23 ELISA wt/wt (A148 NA 4.7± 5.3  Mooney et al. (35), 1997 
    wt/m2 (B10 NA 9.8 ± 8.5 B vs. A P < 0.01  
    wt/wt-GSTM1 active (C78 NA 4.5± 5.8   
    wt/m2-GSTM1 active (DNA 10.5± 7.2  D vs. C P < 0.004  
    wt/wt-GSTM1 0/0 (E70 NA 4.4± 4.7   
    wt/m2-GSTM1 0/0 (FNA  8.7± 11.5   
Polish Caucasian 41± 33 32wt/wt NA NA 3.96± 4.6   Butkiewicz et al. (181), 1998 
    wt/m2 NA NA 5.11± 4.15   
    wt/wt-GSTM1 active NA NA 3.25 ± 3.56 NS  
    wt/m2-active NA NA 0.4 (0.4–0.4)   
    wt/wt-GSTM1 0/0 NA NA 4.80± 5.60   
    wt/m2-GSTM1 0/0 NA NA 6.30± 3.69   
Japanese <20 cig/day 32wt/wt 29 29 1.01± 0.85  Ichiba et al. (182), 1998 
Table 8A

Continued

Study no.EthnicityPY or cig/dayaDetection methodCYP1A1/GSTM1 combinationSubjects (n)Adduct levels (per 108 nucleotides)Effect and significanceReferences
Present (n)Mean ± SD or range
    wt/m2  9  9 0.85 ± 0.54   
    m2/m2  3  3 2.01± 1.04 NS  
    wt/wt-GSTM1 0/0 17 17 1.09± 0.97   
    wt/m2-GSTM1 0/0  4  4 1.64± 1.13   
10 same as #5 French Caucasian 22± 12 HPLC/fd wt/wt-GSTM1 active (A) 15  0 <0.2 A vs. C P < 0.001 Rojas et al. (180), 2000 
    wt/m1 (m2)-GSTM1 active (B)  5  0 <0.2 B vs. D P < 0.001  
    wt/wt-GSTM1 0/0 (C) 16 16 0.7 (0.2–4.1)   
    wt/m1 (m2)-GSTM1 0/0 (D)  8  8 0.9 (0.4–6.1) D vs. C NS  
11 Italian Caucasian 63± 5 GC/MSe wt/wt 38 NA 2.46 ± 0.44  Pastorelli et al. (183), 1998 
    wt/m1  6 NA 3.99± 1.96 NS  
    GSTM1 active 21 NA 2.53± 0.78   
    GSTM1 0/0 23 NA 2.79± 0.56   
Study no.EthnicityPY or cig/dayaDetection methodCYP1A1/GSTM1 combinationSubjects (n)Adduct levels (per 108 nucleotides)Effect and significanceReferences
Present (n)Mean ± SD or range
    wt/m2  9  9 0.85 ± 0.54   
    m2/m2  3  3 2.01± 1.04 NS  
    wt/wt-GSTM1 0/0 17 17 1.09± 0.97   
    wt/m2-GSTM1 0/0  4  4 1.64± 1.13   
10 same as #5 French Caucasian 22± 12 HPLC/fd wt/wt-GSTM1 active (A) 15  0 <0.2 A vs. C P < 0.001 Rojas et al. (180), 2000 
    wt/m1 (m2)-GSTM1 active (B)  5  0 <0.2 B vs. D P < 0.001  
    wt/wt-GSTM1 0/0 (C) 16 16 0.7 (0.2–4.1)   
    wt/m1 (m2)-GSTM1 0/0 (D)  8  8 0.9 (0.4–6.1) D vs. C NS  
11 Italian Caucasian 63± 5 GC/MSe wt/wt 38 NA 2.46 ± 0.44  Pastorelli et al. (183), 1998 
    wt/m1  6 NA 3.99± 1.96 NS  
    GSTM1 active 21 NA 2.53± 0.78   
    GSTM1 0/0 23 NA 2.79± 0.56   
a

PY, pack-years; cig/day, cigarettes per day; NA, not applicable.

b

HPLC/fd, HPLC/fluorescence detection.

c

Limit of detection 0.2 BPDE-DNA adducts per 108 nucleotides.

d

NS, not significant.

e

GC/MS, gas chromatography/mass spectroscopy.

We are indebted to Ulrike Wagner for skilled secretarial help and to Elisabeth Heseltine and Gernhild Bielefeldt for editing.

1
Caporaso N., Goldstein A. Cancer genes—single and susceptibility— exposing the difference.
Pharmacogenetics
,
5
:
59
-63,  
1995
.
2
Vineis P., Bartsch H., Caporaso N., Harrington A. M., Kadlubar F. F., Landi M. T., Malaveille C., Shields P. G., Skipper P., Talaska G., Tannenbaum S. R. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens.
Nature (Lond.)
,
369
:
154
-156,  
1994
.
3
Vineis P. Molecular epidemiology: low-dose carcinogens and genetic susceptibility.
Int. J. Cancer
,
71
:
1
-3,  
1997
.
4
Bartsch H., Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure.
Environ. Health Perspect.
,
104
: (Suppl.3)
569
-577,  
1996
.
5
Doll R. Uncovering the risks of smoking: historical perspective.
Stat. Meth. Med. Res.
,
7
:
87
-117,  
1998
.
6
Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. R., Laughlin R., Nemoto T., Michalek A. M., Harrington A., Ford T. D., Shields P. G. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk.
Cancer Res.
,
55
:
3483
-3485,  
1995
.
7
Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. R., Michalek A. M., Laughlin R., Nemoto T., Gillenwater K. A., Shields P. G. Cigarette smoking, N-acetyltransferase-2 genetic polymorphisms, and breast cancer risk.
J. Am. Med. Assoc.
,
276
:
1494
-1501,  
1996
.
8
Hoffmann D., Hecht S. S. Advances in tobacco carcinogenesis Cooper C. S. Grover P. L. eds. .
Chemical Carcinogenesis and Mutagenesis I
,
63
-103, Springer Berlin  
1990
.
9
Hecht S. S. Tobacco smoke carcinogens and lung cancer.
J. Natl. Cancer Inst.
,
91
:
1194
-1210,  
1999
.
10
McClellan R. O. Tobacco-specific N-nitrosamines.
Recent Adv. Crit. Rev. Toxicol.
,
26
:
119
-253,  
1996
.
11
Bergen A. W., Caporaso N. Cigarette smoking.
J. Natl. Cancer Inst.
,
91
:
1365
-1375,  
1999
.
12
Coles B., Ketterer B. The role of glutathione transferase in chemical carcinogenesis.
CRC Crit. Rev. Biochem. Mol. Biol.
,
25
:
47
-70,  
1990
.
13
Alexandrov K., Rojas M., Geneste O., Castegnaro M., Camus A. M., Petruzzelli S., Giuntini C., Bartsch H. An improved fluorometric assay for dosimetry of benzo[a]pyrene diol-epoxide-DNA adducts in smoker’s lung: comparison with total bulky adducts and aryl hydrocarbon hydroxylase activity.
Cancer Res.
,
52
:
6248
-6253,  
1992
.
14
Kriek E., Rojas M., Alexandrov K., Bartsch H. Polycyclic aromatic hydrocarbon–DNA adducts in humans: relevance as biomarkers for exposure and cancer risk.
Mutat. Res.
,
400
:
215
-231,  
1998
.
15
Hecht S. S. DNA adduct formation from tobacco-specific N-nitrosamines.
Mutat. Res.
,
424
:
127
-142,  
1999
.
16
Bartsch H., Malaveille C., Friesen M., Kadlubar F. F., Vineis P. Smoking and urinary bladder cancer: molecular dosimetry studies in smokers of black and blond tobacco implicate aromatic amines.
Eur. J. Cancer
,
29A
:
1199
-1207,  
1993
.
17
Brockmöller J., Cascorbi I., Kerb R., Sachse C., Roots I. Polymorphisms in xenobiotic conjugation and disease predisposition.
Toxicol. Lett.
,
102–103
:
173
-183,  
1998
.
18
Chung F-L., Chen H-J. C., Nath R. G. Lipid peroxidation as a potential endogenous source for the formation of exocyclic DNA adducts.
Carcinogenesis (Lond.)
,
17
:
2105
-2111,  
1996
.
19
Nair J., Barbin A., Velic I., Bartsch H. Etheno DNA-base adducts from endogenous reactive species.
Mutat. Res.
,
424
:
59
-69,  
1999
.
20
Nath R. G., Ocando J. E., Guttenplan J. B., Chung F-L. 1,N2-Propanodeoxyguanosine adducts: potential new biomarkers of smoking-induced DNA damage in human oral tissue.
Cancer Res.
,
58
:
581
-584,  
1998
.
21
Nair J., Oshima H., Nair U. J., Bartsch H. Endogenous formation of nitrosamines and oxidative DNA-damaging agents in tobacco users.
Crit. Rev. Toxicol.
,
26
:
149
-162,  
1996
.
22
Nair U. J., Nair J., Mathew B., Bartsch H. Glutathione S-transferase M1 and T1 null genotypes as risk factors for oral leukoplakia in ethnic Indian betel quid/tobacco chewers.
Carcinogenesis (Lond.)
,
5
:
743
-748,  
1999
.
23
González F. J. The role of carcinogen-metabolizing enzyme polymorphism in cancer susceptibility.
Reprod. Toxicol.
,
11
:
397
-412,  
1997
.
24
Puga A., Nebert D. W., McKinnon R. A., Menon A. G. Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance.
Crit. Rev. Toxicol.
,
27
:
199
-222,  
1997
.
25
Guengerich F. P., Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes.
Mutat. Res.
,
400
:
201
-213,  
1998
.
26
Cascorbi I., Brockmöller J., Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility.
Cancer Res.
,
56
:
4965
-4969,  
1996
.
27
Nebert D. W., McKinnon R. A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
DNA Cell Biol.
,
15
:
273
-280,  
1996
.
28
Kawajiri K., Watanabe J., Eguchi H., Nakachi K., Kiyohara C., Hayashi S. Polymorphisms of human Ah receptor gene are not involved in lung cancer.
Pharmacogenetics
,
5
:
151
-158,  
1995
.
29
Micka J., Milatovich A., Menon A., Grabowski G. A., Puga A., Nebert D. W. Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility.
Pharmacogenetics
,
7
:
95
-101,  
1997
.
30
Kellerman G., Shaw C. R., Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma.
Engl. J. Med.
,
289
:
934
-937,  
1973
.
31
Peterson D. D., McKinney C. E., Ikeya K., Smith H. H., Bale A. E., McBride O. W., Nebert D. W. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP.
Am. J. Hum. Genet.
,
48
:
720
-725,  
1990
.
32
Landi M. T., Bertazzi P. A., Shields P. G., Clark Lucier, G. W., Garte S. J., Cosma G., Caporaso N. E. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans.
Pharmacogenetics
,
4
:
242
-246,  
1994
.
33
Zhang Z-Y., Fasco M. J., Huang L., Guengerich P., Kaminsky L. S. Characterization of purified human recombinant cytochrome P4501A1-lle462 and Val462: assessment of a role for the rare allele in carcinogenesis.
Cancer Res.
,
56
:
3926
-3933,  
1996
.
34
Persson I., Johansson I., Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility.
Biochem. Biophys. Res. Commun.
,
231
:
227
-230,  
1997
.
35
Mooney L. V., Bell D. A., Santella R. M., Van Bennekum A. M., Ottman R., Paik M., Blaner W. S., Lucier G. W., Covey L., Young T-L., Cooper T. B., Glassman H., Perera F. P. Contribution of genetic and nutritional factors to DNA damage in heavy smokers/TITLE>.
Carcinogenesis (Lond.)
,
18
:
503
-509,  
1997
.
36
Whyatt R. M., Bell D. A., Jedrychowski W., Santella R. M., Garte S. J., Cosma G., Manchester D. K., Young T-L., Cooper T. B., Ottman R., Perera F. P. Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype.
Carcinogenesis (Lond.)
,
8
:
1389
-1392,  
1998
.
37
Vaury C., Laine R., Noguiez P., de Coppet P., Jaulin C., Praz F., Pompon D., Amor-Guéret M. Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription.
Cancer Res.
,
55
:
5520
-5523,  
1995
.
38
Bartsch H. DNA adducts in human carcinogenesis: etiological relevance and structure–activity relationship.
Mutat. Res.
,
340
:
67
-69,  
1996
.
39
Rojas M., Alexandrov K., Cascorbi I., Brockmöller J., Likhachev A., Pozharisski K., Bouvier G., Auburtin G., Mayer L., Koop-Schneider A., Roots I., Bartsch H. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from subjects with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes.
Pharmacogenetics
,
8
:
109
-118,  
1998
.
40
Romkes M., White C., Johnson J., Eibling D., Landreneau R., Branch R. Expression of cytochrome P450 mRNA in human lung, head and neck tumours, and normal adjacent tissues.
Proc. Am. Assoc. Cancer Res.
,
37
:
105
1996
.
41
Lazarus P., Sheikh S. N., Ren Q., Schantz S. P., Stern J. C., Richie J. P., Jr., Park J. Y. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use.
Carcinogenesis (Lond.)
,
19
:
509
-514,  
1998
.
42
Murray G. I., Taylor V. E., McKay J. A., Weaver R. J., Ewen S. W., Melvin W. T., Burke M. D. Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder.
Int. J. Exp. Pathol.
,
76
:
271
-276,  
1995
.
43
Bailey L. R., Roodi N., Verrier C. S., Yee C. J., Dupont W. D., Parl F. F. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans.
Cancer Res.
,
58
:
65
-70,  
1998
.
44
Mace K., Bowman E. D., Vautravers P., Shields P. G., Harris C. C., Pfeifer A. M. Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues.
Eur. J. Cancer
,
34
:
914
-920,  
1998
.
45
Nakajima M., Yokoi T., Mizutani M., Kinoshima M., Funayama M., Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene effect on the CYP1A2 inducibility in humans.
J. Biochem.
,
125
:
803
-808,  
1999
.
46
MacLeod S., Tang Y-M., Yokoi T., Kamataki T., Doublin S., Lawson B., Massengill J., Kadlubar F., Lang N. The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene.
Proc. Am. Assoc. Cancer Res.
,
39
:
396
1998
.
47
Sachse C., Brockmöller J., Bauer S., Roots I. Functional significance of a C→A polymorphism in intron I of the cytochrome P450 CYPIA2 gene tested with caffeine.
Br. J. Clin. Pharmacol.
,
47
:
445
-449,  
1999
.
48
Bartsch H., Rojas M., Alexandrov K., Camus A-M., Castegnaro M., Malaveille C., Anttila S., Hirvonen K., Husgafvel-Pursiainen K., Hietanen E., Vainio H. Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans.
Pharmacogenetics
,
5
:
884
-890,  
1995
.
49
MacLeod S., Sinha R., Kadlubar F. F., Lang N. P. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2.
Mutat. Res.
,
376
:
135
-142,  
1997
.
50
Yu M., Ross R., Chan K. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian men in Los Angeles, California.
J. Natl. Cancer Inst.
,
86
:
712
-716,  
1995
.
51
Bailey L. R., Roodi N., Dupont W. D., Parl F. F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer.
Cancer Res.
,
58
:
5038
-5041,  
1998
.
52
Tiano H. F., Wang R-L., Hosokawa M., Crespi C., Tindall K. R., Langenbach R. Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells.
Carcinogenesis (Lond.)
,
15
:
2859
-2866,  
1994
.
53
Nunoya K., Yokoi T., Kimura K., Inoue K., Kodama T., Funayama M., Nagashima K., Funae Y., Green C., Kinoshita M., Kamataki T. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).
Pharmacogenetics
,
8
:
239
-249,  
1998
.
54
Pianezza M. L., Sellers E. M., Tyndale R. F. Nicotine metabolism defect reduces smoking.
Nature (Lond.)
,
393
:
750
1998
.
55
London S. J., Idle J. R., Daly A. K., Coetzee G. A. Genetic variation of CYP2A6, smoking, and risk of cancer.
Lancet
,
353
:
898
-899,  
1999
.
56
Chen G. F., Tang Y. M., Green B., Lin D. X., Guengerich F. P., Daly A. K., Caporaso N. E., Kadlubar F. F. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method.
Pharmacogenetics
,
9
:
327
-332,  
1999
.
57
Oscarson M., McLellan R. A., Gullsten H., Yue Q. Y., Lang M. A., Bernal M. L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.
FEBS Lett.
,
448
:
105
-110,  
1999
.
58
Ayesh R., Idle J. R., Ritchie J. C., Crothers M. J., Hetzel M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.
Nature (Lond.)
,
312
:
169
-170,  
1984
.
59
Daly A. K., Brockmöller J., Broly F., Eichelbaum M., Evans W. E., Gonzalez F. J., Huang J. D., Idle J. R., Ingelman-Sundberg M., Ishizaki T., Jacqz-Aigrain E., Meyer U. A., Nebert D. W., Stehen V. M., Wolf C. R., Zanger U. M. Nomenclature for human CYP2D6 alleles.
Pharmacogenetics
,
6
:
193
-201,  
1996
.
60
Raunio H., Hakkola J., Hukkanen J., Lassila A., Päivärinta K., Pelkonen O., Anttila S., Piipari P., Boobis A., Edwards R. J. Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue.
Exp. Toxicol. Pathol.
,
51
:
412
-417,  
1999
.
61
Boustead C., Taber H., Idle J. R., Cholerton S. CYP2D6 genotype and smoking behaviour in cigarette smokers.
Pharmacogenetics
,
7
:
411
-414,  
1997
.
62
Saarikoski S. T., Sata F., Husgafvel-Pursiainen K., Rautalahti M., Haukka J., Impivaara O., Järvisalo J., Vainio H., Hirvonen A. CYP2D6 ultrarapid metabolizer genotype as potential modifier of smoking behaviour.
Pharmacogenetics
,
:
in press
2000
.
63
Legrand Andreoletti M., Stucker I., Marez D., Galais P., Cosme J., Sabbagh N., Spire C., Cenee S., Lafitte J. J., Beaune P., Broly F. Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians.
Pharmacogenetics
,
8
:
7
-14,  
1998
.
64
Christensen P. M., Gotzsche P. C., Brosen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Eur. J. Clin. Pharmacol.
,
51
:
389
-393,  
1997
.
65
Rostami Hodjegan A., Lennard M. S., Woods H. F., Tucker G. T. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease.
Pharmacogenetics
,
8
:
227
-238,  
1998
.
66
Chinegwundoh F. I., Kaisary A. V. Polymorphism and smoking in bladder carcinogenesis.
Br. J. Urol.
,
77
:
672
-675,  
1996
.
67
Villard P. H., Seree E. M., Re J. L., De Meo M., Barra Y., Attolini L., Dumenil G., Catalin J., Durand A., Lacarelle B. Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to single strand breaks of DNA.
Toxicol. Appl. Pharmacol.
,
148
:
195
-204,  
1998
.
68
LeMarchand L., Wilkinson G. R., Wilkens L. R. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone.
Cancer Epidemiol. Biomark. Prev.
,
8
:
495
-500,  
1999
.
69
Watanabe J., Hayashi S., Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region.
J. Biochem. (Tokyo)
,
116
:
321
-326,  
1994
.
70
Degawa M., Stern S. J., Martin M. V., Guengerich F. P., Fu P. P., Ilett K. F., Kaderlik R. K., Kadlubar F. F. Metabolic activation and carcinogen-DNA adduct detection in human larynx.
Cancer Res.
,
54
:
4915
-4919,  
1994
.
71
Ozawa S., Schoket B., McDaniel L. P., Tang Y-M., Ambrosone C. B., Kostic S., Vincze I., Kadlubar F. F. Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases.
Carcinogenesis (Lond.)
,
6
:
991
-995,  
1999
.
72
DeMorais S. M. F., Wilkinson G. R., Blaisdell J., Nakamura K., Meyer U. A., Goldstein J. A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
J. Biol. Chem.
,
269
:
15419
-15422,  
1994
.
73
DeMorais S. M. F., Wilkinson G. R., Blaisdell J., Meyer U. A., Nakamura K., Goldstein J. A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Jpn.
Mol. Pharmacol.
,
46
:
594
-598,  
1994
.
74
Patten C. J., Smith T. J., Friesen M. J., Tynes R. E., Yang C. S., Murphy S. E. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N′ nitrosonornicotine α-hydroxylation by human liver microsomes.
Carcinogenesis (Lond.)
,
18
:
1623
-1630,  
1997
.
75
Peyronneau M. A., Renaud J. P., Jaouen M., Urban P., Cullin C., Pompon D., Mansuy D. Expression in yeast of three allelic cDNAs coding for human liver P-450 3A4. Different stabilities, binding properties and catalytic activities of the yeast-produced enzymes.
Eur. J. Biochem./TITLE>
,
218
:
355
-361,  
1993
.
76
Feigelson H. S., Shames L. S., Pike M. C., Coetzee G. A., Stanczyk F. Z., Henderson B. E. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations.
Cancer Res.
,
58
:
585
-587,  
1998
.
77
Polymeropoulos M. H., Xiao H., Rath D. S., Merril C. R. Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19).
Nucleic Acids Res.
,
19
:
195
1991
.
78
Kihara M., Kihara M., Noda K. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population.
Carcinogenesis (Lond.)
,
16
:
2331
-2336,  
1995
.
79
Mollerup S., Ryberg D., Hewer A., Phillips D. H., Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients.
Cancer Res.
,
59
:
3317
-3320,  
1999
.
80
Kawajiri K., Eguchi H., Nakachi K., Sekiya T., Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer.
Cancer Res.
,
56
:
72
-76,  
1996
.
81
Goto M., Yoneda S., Yamamoto M., Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer.
Cancer Res.
,
6
:
3725
-3730,  
1996
.
82
Bartsch H., Hietanen E., Petruzzelli S., Giuntini C., Saracci R., Mussi A., Angeletti C. A. Possible prognostic value of pulmonary Ah locus-linked enzymes in patients with tobacco-related lung cancer.
Int. J. Cancer
,
46
:
185
-188,  
1990
.
83
IARC Application of biomarkers in cancer epidemiology Toniolo P. Boffetta P. Shuker D. Rothman N. Hulka B. Pearce N. eds. .
IARC Sci. Publ. Vol. 142
,
1
-318,  
1997
.
84
IARC Metabolic polymorphisms and susceptibility to cancer Vineis P. Malats M. Lang M. d’Errico A. Caporaso N. Cuzick J. Boffetta P. eds. .
IARC Sci. Publ. Vol. 148
,
1
-510,  
1999
.
85
Kaiser J. Environment institute lays plans for gene hunt.
Science (Washington DC)
,
278
:
569
-570,  
1997
.
86
Nebert D. W., Ingelman-Sundberg M., Daly A. K. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues.
Drug Metab. Rev.
,
31
:
467
-487,  
1999
.
87
Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene.
FEBS Lett.
,
263
:
131
-133,  
1990
.
88
Tefre T., Ryberg D., Haugen A., Nebert D. W., Skaug V., Brogger A., Borresen A. L. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population.
Pharmacogenetics
,
1
:
20
-25,  
1991
.
89
Nakachi K., Imai K., Hayaschi S. I., Watanabe J., Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose.
Cancer Res.
,
51
:
5177
-5180,  
1991
.
90
Hayashi S., Watanabe J., Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and Mu-class glutathione S-transferase genes.
Jpn. J. Cancer Res.
,
83
:
866
-870,  
1992
.
91
Hirvonen A., Husgafvel Pursiainen K., Anttila S., Karjalainen A., Sorsa M., Vainio H. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
Pharmacogenetics
,
2
:
259
-263,  
1992
.
92
Hirvonen A., Husgafvel Pursiainen K., Karjalainen A., Anttila S., Vainio H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population.
Cancer Epidemiol. Biomark. Prev.
,
1
:
485
-489,  
1992
.
93
Hirvonen A., Husgafvel Pursiainen K., Anttila S., Karjalainen A., Vainio H. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.
Environ. Health Perspect.
,
101
: (Suppl. 3)
109
-112,  
1993
.
94
Shields P. G., Caporaso N. E., Falk R. T., Sugimura H., Trivers G. E., Trump B. F., Hoover R. N., Weston A., Harris C. C. Lung cancer, race, and a CYP1A1 genetic polymorphism.
Cancer Epidemiol. Biomark. Prev.
,
2
:
481
-485,  
1993
.
95
Nakachi K., Imai K., Hayashi S., Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population.
Cancer Res.
,
53
:
2994
-2999,  
1993
.
96
Alexandrie A. K., Sundberg M. I., Seidegard J., Tornling G., Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types.
Carcinogenesis (Lond.)
,
15
:
1785
-1790,  
1994
.
97
Kelsey K. T., Wiencke J. K., Spitz M. R. A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans.
Carcinogenesis (Lond.)
,
15
:
1121
-1124,  
1994
.
98
Okada T., Kawashima K., Fukushi S., Minakuchi T., Nishimura S. Association between a cytochrome P450 CYP1A1 genotype and incidence of lung cancer.
Pharmacogenetics
,
4
:
333
-340,  
1994
.
99
Sugimura H., Hamada G. S., Suzuki I., Iwase T., Kiyokawa E., Kino I., Tsugane S. CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil.
Pharmacogenetics
,
Spec. No. 5
:
145
-148,  
1994
.
100
Hamada G. S., Sugimura H., Suzuki I., Nagura K., Kiyokawa E., Iwase T., Tanaka M., Takahashi T., Watanabe S., Kino I., Tsugane S. The heme-binding region polymorphism of cytochrome P450IA1 (CypIA1), rather than the RsaI polymorphism of IIE1 (CypIIE1), is associated with lung cancer in Rio de Janeiro.
Cancer Epidemiol. Biomark. Prev.
,
4
:
63
-67,  
1995
.
101
Sugimura H., Suzuki I., Hamada G. S., Iwase T., Takahashi T., Nagura K., Iwata H., Watanabe S., Kino I., Tsugane S. Cytochrome P-450 lA1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil.
Cancer Epidemiol. Biomark. Prev.
,
3
:
145
-148,  
1994
.
102
London S. J., Daly A. K., Fairbrother K. S., Holmes C., Carpenter C. L., Navidi W. C., Idle J. R. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism [see comments].
Cancer Res.
,
55
:
6035
-6037,  
1995
.
103
Drakoulis N., Cascorbi I., Brockmöller J., Gross C. R., Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon 7 mutation (4889 A to G) and a T to C mutation in the 3′-flanking region.
Clin. Investig.
,
72
:
240
-248,  
1994
.
104
Jacquet M., Lambert V., Baudoux E., Muller M., Kremers P., Gielen J. Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence.
Eur. J. Cancer
,
32A
:
1701
-1706,  
1996
.
105
Xu X., Kelsey K. T., Wiencke J. K., Wain J. C., Christiani D. C. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility.
Cancer Epidemiol. Biomark. Prev.
,
5
:
687
-692,  
1996
.
106
Garcia Closas M., Kelsey K. T., Wiencke J. K., Xu X., Wain J. C., Christiani D. C. A case–control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States).
Cancer Causes Control
,
8
:
544
-553,  
1997
.
107
Ishibe N., Wiencke J. K., Zuo Z. F., McMillan A., Spitz M., Kelsey K. T. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans.
Cancer Epidemiol. Biomark. Prev.
,
6
:
1075
-1080,  
1997
.
108
Bouchardy C., Wikman H., Benhamou S., Hirvonen A., Dayer P., Husgafvel-Pursiainen K. CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population.
Biomarkers
,
2
:
131
-134,  
1997
.
109
Le Marchand L., Sivaraman L., Pierce L., Seifried A., Lum A., Wilkens L. R., Lau A. F. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens.
Cancer Res.
,
58
:
4858
-4863,  
1998
.
110
Taioli E., Ford J., Trachman J., Li Y., Demopoulos R., Garte S. Lung cancer risk and CYP1A1 genotype in African Americans.
Carcinogenesis (Lond.)
,
19
:
813
-817,  
1998
.
111
Taioli E., Crofts F., Trachman J., Demopoulos R., Toniolo P., Garte S. J. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung.
Cancer Res.
,
55
:
472
-473,  
1995
.
112
Sugimura H., Wakai K., Genka K., Nagura K., Igarashi H., Nagayama K., Ohkawa A., Baba S., Morris B. J., Tsugane S., Ohno Y., Gao C., Li Z., Takezaki T., Tajima K., Iwamasa T. Association of Ile462Val (exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa.
Cancer Epidemiol. Biomark. Prev.
,
7
:
413
-417,  
1998
.
113
Kiyohara C., Nakanishi Y., Inutsuka A., Takayama K., Hara N., Motohiro A., Tanaka K., Kono S., Hirohata T. The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population.
Pharmacogenetics
,
8
:
315
-323,  
1998
.
114
Persson I., Johansson I., Lou Y. C., Yue Q. Y., Duan L. S., Bertilsson L., Ingelman Sundberg M Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients.
Int. J. Cancer
,
81
:
325
-329,  
1999
.
115
Hong Y. S., Chang J. H., Kwon O. J., Ham Y. A., Choi J. H. Polymorphism of the CYP1A1 and glutathione-S-transferase gene in Korean lung cancer patients.
Exp. Mol. Med.
,
30
:
192
-198,  
1998
.
116
Smith C. A., Moss J. E., Gough A. C., Spurr N. K., Wolf C. R. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.
Environ. Health Perspect.
,
98
:
107
-112,  
1992
.
117
Wolf C. R., Dale Smith C. A., Gough A. C., Moss J. E., Vallis K. A., Howard G., Garey F. J., Mills K., McNee W., Carmichael J., Spurr N. K. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility.
Carcinogenesis (Lond.)
,
13
:
1035
-1038,  
1992
.
118
Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Pelkonen O., Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Pharmacogenetics
,
3
:
19
-27,  
1993
.
119
Agundez J. A., Martinez C., Ladero J. M., Ledesma M. C., Ramos J. M., Martin R., Rodriguez A., Jara C., Benitez J. Debrisoquin oxidation genotype and susceptibility to lung cancer.
Clin. Pharmacol. Ther.
,
55
:
10
-14,  
1994
.
120
Tefre T., Daly A. K., Armstrong M., Leathart J. B., Idle J. R., Brogger A., Borresen A. L. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls.
Pharmacogenetics
,
4
:
47
-57,  
1994
.
121
Dolzan V., Rudolf Z., Breskvar K. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
Carcinogenesis (Lond.)
,
16
:
2675
-2678,  
1995
.
122
El Zein R., Zwischenberger J. B., Wood T. G., Abdel Rahman S. Z., Brekelbaum C., Au W. W. Combined genetic polymorphism and risk for development of lung cancer.
Mutat. Res.
,
381
:
189
-200,  
1997
.
123
El Zein R., Conforti Froes N., Au W. W. Interactions between genetic predisposition and environmental toxicants for development of lung cancer.
Environ. Mol. Mutagen.
,
30
:
196
-204,  
1997
.
124
London S. J., Daly A. K., Leathart J. B., Navidi W. C., Carpenter C. C., Idle J. R. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County.
Carcinogenesis (Lond.)
,
18
:
1203
-1214,  
1997
.
125
Legrand M., Stucker I., Marez D., Sabbagh N., Lo Guidice J. M., Broly F. Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility.
Carcinogenesis (Lond.)
,
17
:
2267
-2269,  
1996
.
126
Stücker I., Cosme J., Laurent P., Cenee S., Beaune P., Bignon J., Depierre A., Milleron B., Hemon D. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure.
Carcinogenesis (Lond.)
,
16
:
2759
-2764,  
1995
.
127
Shaw G. L., Falk R. T., Frame J. N., Weiffenbach B., Nesbitt J. C., Pass H. I., Caporaso N. E., Moir D. T., Tucker M. A. Genetic polymorphism of CYP2D6 and lung cancer risk.
Cancer Epidemiol Biomark. Prev.
,
7
:
215
-219,  
1998
.
128
Shaw G. L., Weiffenbach B., Falk R. T., Frame J. N., Issaq H. J., Moir D. T., Caporaso N. Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls.
Lung Cancer
,
17
:
61
-68,  
1997
.
129
Uematsu F., Kikuchi H., Motomiya M., Abe T., Sagami I., Ohmachi T., Wakui A., Kanamaru R., Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer.
Jpn. J. Cancer Res.
,
82
:
254
-256,  
1991
.
130
Uematsu F., Kikuchi H., Motomiya M., Abe T., Ishioka C., Kanamaru R., Sagami I., Watanabe M. Human cytochrome P450IIE1 gene: DraI polymorphism and susceptibility to cancer.
Tohoku J. Exp. Med.
,
168
:
113
-117,  
1992
.
131
Uematsu F., Ikawa S., Kikuchi H., Sagami I., Kanamaru R., Abe T., Satoh K., Motomiya M., Watanabe M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure.
Pharmacogenetics
,
4
:
58
-63,  
1994
.
132
Kato S., Shields P. G., Caporaso N. E., Hoover R. N., Trump B. F., Sugimura H., Weston A., Harris C. C. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk.
Cancer Res.
,
52
:
6712
-6715,  
1992
.
133
Hirvonen A., Husgafvel Pursiainen K., Anttila S., Karjalainen A., Vainio H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population.
Carcinogenesis (Lond.)
,
14
:
85
-88,  
1993
.
134
Persson I., Johansson I., Bergling H., Dahl M. L., Seidegard J., Rylander R., Rannug A., Hogberg J., Sundberg M. I. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer.
FEBS Lett.
,
319
:
207
-211,  
1993
.
135
Kato S., Shields P. G., Caporaso N. E., Sugimura H., Trivers G. E., Tucker M. A., Trump B. F., Weston A., Harris C. C. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer.
Cancer Epidemiol. Biomark. Prev.
,
3
:
515
-518,  
1994
.
136
Watanabe J., Yang J. P., Eguchi H., Hayashi S., Imai K., Nakachi K., Kawajiri K. An RsaI polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population.
Jpn. J. Cancer Res.
,
86
:
245
-248,  
1995
.
137
London S. J., Daly A. K., Cooper J., Carpenter C. L., Navidi W. C., Ding L., Idle J. R. Lung cancer risk in relation to the CYP2E1 RsaI genetic polymorphism among African-Americans and Caucasians in Los Angeles County.
Pharmacogenetics
,
6
:
151
-158,  
1996
.
138
Oyama T., Kawamoto T., Mizoue T., Sugio K., Kodama Y., Mitsudomi T., Yasumoto K. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer in relation to p53 gene mutation.
Anticancer Res.
,
17
:
583
-587,  
1997
.
139
El Zein R. A., Zwischenberger J. B., Abdel Rahman S. Z., Sankar A. B., Au W. W. Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma.
Cancer Lett.
,
112
:
71
-78,  
1997
.
140
Wu X., Shi H., Jiang H., Kemp B., Hong W. K., Delclos G. L., Spitz M. R. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer.
Carcinogenesis (Lond.)
,
18
:
967
-973,  
1997
.
141
Wu X., Amos C. I., Kemp B. L., Shi H., Jiang H., Wan Y., Spitz M. R. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations.
Cancer Epidemiol. Biomark. Prev.
,
7
:
13
-18,  
1998
.
142
London S. J., Daly A. K., Leathart J. B., Navidi W. C., Idle J. R. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
Pharmacogenetics
,
6
:
527
-533,  
1996
.
143
London S. J., Sullivan Klose T., Daly A. K., Idle J. R. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County.
Pharmacogenetics
,
7
:
401
-404,  
1997
.
144
Tsuneoka Y., Fukushima K., Matsuo Y., Ichikawa Y., Watanabe Y. Genotype analysis of the CYP2C19 gene in the Japanese population.
Life Sci.
,
59
:
1711
-1715,  
1996
.
145
Lucas D., Menez C., Floch F., Gourlaouen Y., Sparfel O., Joannet I., Bodenez P., Jezequel J., Gouerou H., Berthou F., Bardou L. G., Menez J. F. Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic Caucasians.
Alcohol Clin. Exp. Res.
,
20
:
1033
-1037,  
1996
.
146
Park J. Y., Muscat J. E., Ren Q., Schantz S. P., Harwick R. D., Stern J. C., Pike V., Richie J. P., Jr., Lazarus P. CYP1A1 and GSTM1 polymorphisms and oral cancer risk [published erratum appears in Cancer Epidemiol. Biomark. Prev., 6: 1108, 1997].
Cancer Epidemiol. Biomark. Prev.
,
6
:
791
-797,  
1978
.
147
Matthias C., Bockmuhl U., Jahnke V., Jones P. W., Hayes J. D., Alldersea J., Gilford J., Bailey L., Bath J., Worrall S. F., Hand P., Fryer A. A., Strange R. C. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
Pharmacogenetics
,
8
:
91
-100,  
1998
.
148
Oude Ophuis M. B., van Lieshout E. M., Roelofs H. M., Peters W. H., Manni J. J. Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions.
Cancer (Phila.)
,
82
:
936
-943,  
1998
.
149
Morita S., Yano M., Tsujinaka T., Akiyama Y., Taniguchi M., Kaneko K., Miki H., Fujii T., Yoshino K., Kusuoka H., Monden M. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma.
Int. J. Cancer
,
80
:
685
-688,  
1999
.
150
Tanimoto K. S., Hayashi S., Yoshiga K., Ichikawa T. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose.
Oral Oncol.
,
35
:
191
-196,  
1999
.
151
Gonzalez M. V., Alvarez V., Pello M. F., Menendez M. J., Suarez C., Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer.
J. Clin. Pathol.
,
51
:
294
-298,  
1998
.
152
Worrall S. F., Corrigan M., High A., Starr D., Matthias C., Wolf C. R., Jones P. W., Hand P., Gilford J., Farrell W. E., Hoban P., Fryer A. A., Strange R. C. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6.
Pharmacogenetics
,
8
:
433
-439,  
1998
.
153
Hung H. C., Chuang J., Chien Y. C., Chern H. D., Chiang C. P., Kuo Y. S., Hildesheim A., Chen C. J. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1: environmental factors and risk of oral cancer.
Cancer Epidemiol. Biomark. Prev.
,
6
:
901
-905,  
1997
.
154
Hori H., Kawano T., Endo M., Yuasa Y. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility.
J. Clin. Gastroenterol.
,
25
:
568
-575,  
1997
.
155
Morita S., Yano M., Shiozaki H., Tsujinaka T., Ebisui C., Morimoto T., Kishibuti M., Fujita J., Ogawa A., Taniguchi M., Inoue M., Tamura S., Yamazaki K., Kikkawa N., Mizunoya S., Monden M. CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus.
Int. J. Cancer
,
71
:
192
-195,  
1997
.
156
Nimura Y., Yokoyama S., Fujimori M., Aoki T., Adachi W., Nasu T., He M., Ping Y. M., Iida F. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking.
Cancer (Phila.)
,
80
:
852
-857,  
1997
.
157
Van Lieshout E. M., Roelofs H. M., Dekker S., Mulder C. J., Wobbes T., Jansen J. B., Peters W. H. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett’s esophagus and esophageal carcinoma.
Cancer Res.
,
59
:
586
-589,  
1999
.
158
Lin D. X., Tang Y. M., Peng Q., Lu S. X., Ambrosone C. B., Kadlubar F. F. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1.
Cancer Epidemiol. Biomark. Prev.
,
7
:
1013
-1018,  
1998
.
159
Katoh T., Inatomi H., Nagaoka A., Sugita A. Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients.
Carcinogenesis (Lond.)
,
16
:
655
-657,  
1995
.
160
Brockmöller J., Cascorbi I., Kerb R., Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Cancer Res.
,
56
:
3915
-3925,  
1996
.
161
Spurr N. K., Gough A. C., Chinegwundoh F. I., Smith C. A. Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk.
Clin. Chem.
,
41
:
1864
-1869,  
1995
.
162
Anwar W. A., Abdel Rahman S. Z., El Zein R. A., Mostafa H. M., Au W. W. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients.
Carcinogenesis (Lond.)
,
17
:
1923
-1929,  
1996
.
163
Farker K., Lehmann M. H., Oelschlagel B., Haerting J., Hoffmann A., Janitzky V., Schubert J. Impact of CYP2E1 genotype in renal cell and urothelial cancer patients.
Exp. Toxicol. Pathol.
,
50
:
425
-431,  
1998
.
164
Rebbeck T. R., Rosvold E. A., Duggan D. J., Zhang J., Buetow K. H. Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer.
Cancer Epidemiol. Biomark. Prev.
,
3
:
511
-514,  
1994
.
165
Taioli E., Trachman J., Chen X., Toniolo P., Garte S. J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women.
Cancer Res.
,
55
:
3757
-3758,  
1995
.
166
Ishibe N., Hankinson S. E., Colditz G. A., Spiegelman D., Willett W. C., Speizer F. E., Kelsey K. T., Hunter D. J. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses’ Health Study.
Cancer Res.
,
58
:
667
-671,  
1998
.
167
Moysich K. B., Shields P. G., Freudenheim J. L., Schisterman E. F., Vena J. E., Kostyniak P., Greizerstein H., Marshall J. R., Graham S., Ambrosone C. B. Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk.
Cancer Epidemiol. Biomark. Prev.
,
8
:
41
-44,  
1999
.
168
Buchert E. T., Woosley R. L., Swain S. M., Oliver S. J., Coughlin S. S., Pickle L., Trock B., Riegel A. T. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility.
Pharmacogenetics
,
3
:
322
-327,  
1993
.
169
Ladona M. G., Abildua R. E., Ladero J. M., Roman J. M., Plaza M. A., Agundez J. A., Munoz J. J., Benitez J. CYP2D6 genotypes in Spanish women with breast cancer.
Cancer Lett.
,
99
:
23
-28,  
1996
.
170
Shields P. G., Ambrosone C. B., Graham S., Bowman E. D., Harrington A. M., Gillenwater K. A., Marshall J. R., Vena J. E., Laughlin R., Nemoto T., Freudenheim J. L. A cytochrome P4502E1 genetic polymorphism and tobacco smoking in breast cancer.
Mol. Carcinog.
,
17
:
144
-150,  
1996
.
171
Feigelson H. S., Coetzee G. A., Kolonel L. N., Ross R. K., Henderson B. E. A polymorphism in the CYP17 gene increases the risk of breast cancer.
Cancer Res.
,
57
:
1063
-1065,  
1997
.
172
Dunning A. M., Healey C. S., Pharoah P. D., Foster N. A., Lipscombe J. M., Redman K. L., Easton D. F., Day N. E., Ponder B. A. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer.
Br. J. Cancer
,
77
:
2045
-2047,  
1998
.
173
Helzlsouer K. J., Harris E. L., Parshad R., Perry H. R., Price F. M., Sanford K. K. DNA repair proficiency: potential susceptibility factor for breast cancer.
J. Natl. Cancer Inst.
,
88
:
754
-755,  
1996
.
174
Weston A., Pan C. F., Bleiweiss I. J., Ksieski H. B., Roy N., Maloney N., Wolff M. S. CYP17 genotype and breast cancer risk.
Cancer Epidemiol. Biomark. Prev.
,
7
:
941
-944,  
1998
.
175
Haiman C. A., Hankinson S. E., Spiegelman D., Colditz G. A., Willett W. C., Speizer F. E., Kelsey K. T., Hunter D. J. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Cancer Res.
,
59
:
1015
-1020,  
1999
.
176
Kristensen V. N., Andersen T. I., Lindblom A., Erikstein B., Magnus P., Borresen Dale A. L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer.
Pharmacogenetics
,
8
:
43
-48,  
1998
.
177
Siegelmann Danieli N., Buetow K. H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk.
Br. J. Cancer
,
79
:
456
-463,  
1999
.
178
Schoket B., Philips D. H., Poirier M. C., Kostic S., Vincze I. Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 and GSTM1 genotypes in lung patients.
Carcinogenesis (Lond.)
,
19
:
841
-846,  
1998
.
179
Ichiba M., Hagmar L., Rannug A., Högstedt B., Alexandrie A-K., Carstensen U., Hemminki K. Aromatic DNA adducts, micronuclei and genetic polymorphism for CYP1A1 and GSTM1 in chimney sweeps.
Carcinogenesis (Lond.)
,
15
:
1347
-1352,  
1994
.
180
Rojas M., Cascorbi I., Alexandrov K., Kriek E., Auburtin G., Mayer L., Koop-Schneider A., Roots I., Bartsch H. Modulation of benzo(a)pyrene diolepoxide-DNA adducts in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism.
Carcinogenesis
,
21
:
in press
2000
.
181
Butkiewicz D., Grzybowska E., Hemminki H., Øvrebø S., Haugen A., Motykiewicz G., Chorazy M. Modulation of DNA adduct levels in human mononuclear white blood cells and granulocytes by CYP1A1, CYP2D6 and GSTM1 genetic polymorphisms.
Mutat. Res.
,
415
:
97
-108,  
1998
.
182
Ichiba M., Wang Y. P., Oishi H., Zhang J. S., Iyadomi M., Minagawa M., Tomokuni K. Lymphocytes, DNA adducts and genetic polymorphism for metabolic enzymes in low dose cigarette smokers.
Biomarkers
,
3
:
63
-71,  
1998
.
183
Pastorelli R., Guanci M., Cerri A., Negri E., La Vecchia C., Fumagalli F., Mezzetti M., Cappelli R., Panigalli T., Fanelli R., Airoldi L. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide.
Cancer Epidemiol. Biomark. Prev.
,
7
:
703
-709,  
1998
.